Bell's palsy

Complex MONDO:0005665 Pathograph 22 Show in embeddings browser Neurological Disorder Peripheral Neuropathy

Bell's palsy is an acute idiopathic peripheral facial neuropathy, usually producing unilateral weakness of the upper and lower face. Inflammatory swelling and compression of cranial nerve VII in the facial canal form the leading mechanistic model, while the initiating cause remains uncertain. Viral reactivation and common genetic susceptibility are proposed contributors. Most patients improve over weeks to months, but axonal injury can leave persistent weakness or synkinesis.

Ask OpenScientist

Ask a research question about Bell's palsy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Mappings
1
Definitions
9
Pathophys.
9
Phenotypes
1
Hypotheses
2
Gaps
22
Pathograph
1
Genes
9
Medical Actions
5
Differentials
6
Trials
1
Models
31
References
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
🔗

Mappings

MONDO
MONDO:0005665 Bell's palsy
skos:exactMatch MONDO
Primary MONDO disease identifier for this Bell's palsy entry.
ICD-10-CM
ICD10CM:G51.0 Bell's palsy
skos:exactMatch ICD-10-CM
Bell's palsy is represented directly by ICD-10-CM code G51.0.
📘

Definitions

1
Clinical syndrome definition for Bell's palsy
Acute unilateral peripheral facial weakness or paralysis of unknown cause after clinical exclusion of alternative etiologies; weakness develops rapidly, usually over hours to two days.
CASE_DEFINITION General clinical framing of acute idiopathic peripheral facial palsy
Show evidence (2 references)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Bell's palsy is acute weakness of the facial muscles associated with compression of cranial nerve VII."
This directly supports the standard clinical definition of Bell's palsy as acute cranial-nerve-VII-mediated facial weakness.
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Bell's palsy, also known as "acute facial palsy of unknown cause", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
This supports the idiopathic acute cranial-neuropathy framing and typical time course.
◈

Mechanistic Hypotheses

1
Herpesvirus reactivation as a possible initiating event
VIRAL_REACTIVATION ALTERNATIVE
Evidence balance 1 support
HSV-1 reactivation is a plausible initiating hypothesis supported by viral-DNA detection in selected clinical samples. It is not a demonstrated universal cause, and trials of antiviral treatment do not provide consistent evidence for added complete-recovery benefit.
Pathograph links
Putative herpesvirus reactivation -> Facial nerve inflammation INDIRECT UNKNOWN INTERMEDIATES Proposed viral initiation of local inflammation; causality is unresolved.
Show evidence (1 reference)
PMID:7503474 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls."
This human molecular observation is evidence for a viral hypothesis, not proof that all Bell's palsy is infectious.
?

Discussions and Knowledge Gaps

2
Which inflammatory protein associations contribute causally to idiopathic facial nerve injury?
EMERGING HYPOTHESIS OPEN INFLAMMATORY_PROTEOMICS
A 2025 Mendelian-randomization and protein-network study nominated JAK/STAT-related inflammatory candidates. It used relaxed instrument thresholds, nominal testing and computational network hubs without direct facial-nerve experiments. The table reports low shared-variant posterior probabilities for CCL19, VCAM1, IL27RA and OSM (approximately 0.007-0.022), despite stronger claims in the discussion. These findings do not establish a causal edge from JAK/STAT activation to facial nerve edema or a clinical role for JAK inhibitors.
Show evidence (2 references)
PMID:40299566 SUPPORT DIRECT PRIMARY RESULT Computational
"Four proteins, VCAM-1 (PP.H4: 0.022), CCL19 (PP.H4: 0.007), OSM (PP.H4: 0.011), and IL27RA (PP.H4: 0.02)"
These reported low PP.H4 values support the discussion's conclusion that shared causal variants have not been established; SUPPORT refers to that limitation, not to the proposed inflammatory causality.
PMID:40299566 SUPPORT DIRECT PRIMARY RESULT Computational
"composed of six hub proteins: JAK2, IL27RA, OSM, CCL19, SELL, and VCAM-1."
Protein-network analysis nominated these hubs; it did not measure pathway activation in an affected human facial nerve.
Does SLIT2-ROBO signaling modify repair in human idiopathic facial palsy?
HUMAN MODEL MISMATCH OPEN SLIT2_REPAIR
A 2025 study combined Bell's palsy genetic associations with single-cell profiling and SLIT2 immunofluorescence in rat facial motor nuclei after mechanical nerve crush. Nominal plasma-protein MR associations and altered expression generate a repair hypothesis. Its PPH3+PPH4 threshold combines distinct-variant and shared-variant hypotheses and therefore does not by itself prove colocalization. CellChat and pseudotime are computational inferences; no SLIT2 perturbation or therapeutic rescue was performed. The rat lesion and central nuclear response do not reproduce the unknown initiating cause of human Bell's palsy.
Show evidence (2 references)
PMID:41099890 SUPPORT DIRECT PRIMARY RESULT Computational
"Due to the limited power of colocalization analysis, we focused on genes with a combined posterior probability (PPH3 + PPH4) ≥ 0.8"
A sum including PPH3 cannot establish that exposure and disease share a single causal variant.
PMID:41099890 SUPPORT DIRECT PRIMARY RESULT Model Organism
"Immunofluorescence experiments further confirmed that SLIT2 protein expression in facial-nerve nucleus samples from the facial-nerve injury group was significantly higher than that in the control group"
Increased expression after a mechanical rat nerve injury is not proof of a causal or therapeutic SLIT2 effect in human idiopathic disease.
⚙

Pathophysiology

9
Putative herpesvirus reactivation
Reactivation of latent HSV-1 is one proposed initiating event, not an established cause in every idiopathic case. A small prospective study detected HSV-1 DNA in endoneurial fluid or posterior auricular muscle from 11 of 14 Bell's palsy patients, compared with none of nine Ramsay Hunt patients and twelve other controls. Detection in selected clinical samples supports the hypothesis but does not establish timing, causal sufficiency or population prevalence.
Herpesvirus reactivation as a possible initiating event
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial nerve inflammation Proposed viral initiation of local inflammation; causality is unresolved. Herpesvirus reactivation as a possible initiating event
Show evidence (1 reference)
PMID:7503474 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls."
This human molecular observation is evidence for a viral hypothesis, not proof that all Bell's palsy is infectious.
Facial nerve inflammation
Local inflammation around the facial nerve is a leading explanatory process. The initiating event and relative contributions of viral reactivation, immune responses and vascular factors remain unresolved.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial nerve edema within the facial canal Inflammatory injury is modeled as upstream of swelling.
Show evidence (1 reference)
PMID:33602968 SUPPORT DIRECT BACKGROUND Human Clinical
"While the pathogenesis remains unknown, previous studies have implicated post-viral inflammation and resulting compression of the facial nerve."
The GWAS introduction summarizes the inflammatory model rather than experimentally demonstrating it.
Facial nerve edema within the facial canal
Swelling of the facial nerve within the narrow bony facial canal limits its ability to expand. This is the proposed anatomical substrate for secondary compression.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial nerve compression Swelling within a confined canal produces local compression.
Facial nerve axonal injury More severe inflammatory lesions may include axonal degeneration.
Show evidence (1 reference)
PMID:35160337 SUPPORT DIRECT BACKGROUND Human Clinical
"The pathophysiology of Bell’s palsy includes edematous swelling of the facial nerve within the Fallopian canal, which causes a conduction block and subsequent dysfunction."
The surgical study's background summarizes the anatomical model; its operative comparison is separate evidence.
Facial nerve compression
The rigid intratemporal canal constrains a swollen facial nerve, producing local compression, particularly at narrow segments. Anatomical compression is distinct from the resulting conduction failure and from axonal degeneration.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial nerve conduction impairment Local mechanical constraint can impair nerve conduction.
Show evidence (1 reference)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"As a result of this viral infection, the facial nerve swells and is compressed in its canal as it courses through the temporal bone."
The guideline describes compression in a proposed viral-inflammatory model; the viral antecedent is not independently proven by this review.
Facial nerve conduction impairment
Reduced conduction through affected facial nerve fibers produces lower motor neuron facial weakness and can disturb facial-nerve-associated taste, stapedius function and tear secretion. In neurapraxia, conduction block occurs without axonal disruption and can recover without the regeneration required for synkinesis.
peripheral nervous system neuron CL:2000032 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves peripheral nervous system neuron (CL:2000032). CL:2000032 is a cell type from the Cell Ontology.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial weakness Impaired motor output weakens the facial musculature.
Lagophthalmos Orbicularis oculi weakness prevents complete eyelid closure.
Abnormal taste sensation Associated taste-fiber dysfunction alters taste sensation.
Hyperacusis Stapedius pathway dysfunction reduces normal sound attenuation.
Dry eyes Parasympathetic involvement can reduce tear secretion.
Ocular surface exposure Impaired blink and eyelid closure expose the ocular surface.
Show evidence (1 reference)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Many patients with Bell's palsy fortunately only develop neurapraxia, i.e., a transient blockage of facial nerve conduction without axonal damage"
This explicitly distinguishes reversible conduction block from axonal injury.
Facial nerve axonal injury
More severe lesions include axonal degeneration rather than isolated neurapraxia. Wallerian degeneration reaches distal segments after a delay, explaining why early distal electrical responses may remain intact. Axonal injury increases the possibility of incomplete recovery and creates the substrate for abnormal reinnervation.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Mechanical facial nerve crush in Sprague-Dawley rats Rattus norvegicus partially recapitulates Mechanical nerve crush produces a peripheral injury with a subsequent central facial-nucleus response.
Downstream
Misguided facial motor axon regeneration Regeneration after axonal injury may be misdirected; this does not occur after pure neurapraxia.
Misdirected secretomotor reinnervation of the lacrimal gland Abnormal reinnervation after a proximal facial nerve lesion may involve autonomic as well as motor fibers.
Show evidence (1 reference)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Only those patients with Bell's palsy and axonal damage can develop facial synkinesis."
The synkinesis review identifies axonal damage as a prerequisite, not a universal feature of Bell's palsy.
Misguided facial motor axon regeneration
Regenerating motor axons may send collateral sprouts into inappropriate facial nerve branches, coupling muscles that should move independently. This established regeneration model explains post-paralytic synkinesis; ephaptic transmission and central remodeling are additional proposed contributors with different levels of evidence.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Facial synkinesis Collateral innervation couples intended and unintended facial movements.
Show evidence (2 references)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The synkinesis is a result of misguided nerve regeneration following axonal damage."
This supports aberrant regeneration as the principal explanatory process for synkinesis.
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Facial synkinesis occurs when one axon sends sprouts to muscle fibers of two different muscles, i.e., the original target muscle and any other muscle."
The full text describes the specific branching error rather than inferring regeneration from a drug trial.
Misdirected secretomotor reinnervation of the lacrimal gland
Aberrant reinnervation can redirect meal-associated secretomotor output to the lacrimal gland through the greater superficial petrosal nerve. This autonomic miswiring produces gustatory tearing and is distinct from motor-axon branching into facial muscles.
facial nerve UBERON:0001647 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in facial nerve (UBERON:0001647). UBERON:0001647 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Gustatory lacrimation Eating triggers tearing through the misdirected secretomotor connection.
Show evidence (1 reference)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Another rare symptom is gustatory hyperlacrimation (crocodile tears) induced by misdirected reinnervation of gustatory fibers through the greater superficial petrosal nerve to reach the lacrimal gland. This results in tearing when the patient eats (38)."
The review describes gustatory tearing as an autonomic sequela of misdirected reinnervation.
Ocular surface exposure
Impaired blinking and eyelid closure expose the cornea; inadequate lubrication can result in epithelial injury, exposure keratitis and corneal ulceration. This is a secondary complication of facial dysfunction, not a primary cause of the neuropathy.
Downstream
Corneal ulceration Unprotected exposure can damage the corneal epithelium.
Show evidence (1 reference)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Failure to protect the cornea among patients who are unable to blink adequately may result in corneal ulceration and permanent visual impairment."
The guideline directly links inadequate protection in impaired blinking with corneal complications.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bell's palsy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 1
Dry eyes Keratoconjunctivitis sicca HP:0001097 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Keratoconjunctivitis sicca (HP:0001097). HP:0001097 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations in taste, and dry eyes caused by parasympathetic affliction."
Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
Eye 2
Corneal ulceration HP:0012804 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Corneal ulceration (HP:0012804). HP:0012804 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Failure to protect the cornea among patients who are unable to blink adequately may result in corneal ulceration and permanent visual impairment."
The guideline directly links inadequate protection in impaired blinking with corneal complications.
Gustatory lacrimation HP:0100274 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gustatory lacrimation (HP:0100274). HP:0100274 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Another rare symptom is gustatory hyperlacrimation (crocodile tears) induced by misdirected reinnervation of gustatory fibers through the greater superficial petrosal nerve to reach the lacrimal gland. This results in tearing when the patient eats (38)."
The review describes gustatory tearing as an autonomic sequela of misdirected reinnervation.
Head and Neck 3
Facial weakness OBLIGATE Weakness of facial musculature HP:0030319 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is acute unilateral peripheral facial weakness, annotated with Weakness of facial musculature (HP:0030319). HP:0030319 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Bell's palsy, also known as "acute facial palsy of unknown cause", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
This directly supports acute unilateral peripheral facial weakness as the core phenotype of Bell's palsy.
Lagophthalmos HP:0030001 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is lagophthalmos (HP:0030001). HP:0030001 is a phenotype from the Human Phenotype Ontology.
Sequelae: Ocular surface exposure
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Symptoms of Bell's palsy include the inability to blink or close the eye, ruck up the lips or raise the mouth corner"
The review describes motor manifestations of peripheral facial nerve dysfunction.
Abnormal taste sensation Abnormality of taste sensation HP:0000223 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is altered taste sensation, annotated with Abnormality of taste sensation (HP:0000223). HP:0000223 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations in taste, and dry eyes caused by parasympathetic affliction."
Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
Nervous System 2
Hyperacusis HP:0010780 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is hyperacusis (HP:0010780). HP:0010780 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations in taste, and dry eyes caused by parasympathetic affliction."
Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
Facial synkinesis HP:0034979 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is facial synkinesis (HP:0034979). HP:0034979 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The synkinesis is a result of misguided nerve regeneration following axonal damage."
This supports aberrant regeneration as the principal explanatory process for synkinesis.
Constitutional 1
Ear pain HP:0030766 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ear pain (HP:0030766). HP:0030766 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Facial pain: usually mild pain in the face or behind the ear (common in Bell palsy)"
The guideline describes mild facial or postauricular discomfort; it does not establish a numeric frequency.
🧬

Genetic Associations

1
Common susceptibility locus at 6p21.1 (SUSCEPTIBILITY)
Show evidence (3 references)
PMID:33602968 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Here, we report findings from a meta-analysis of genome-wide association studies uncovering the first unequivocal association with Bell's palsy (rs9357446-A; P = 6.79 × 10-23, OR = 1.23; Ncases = 4714, Ncontrols = 1,011,520)."
This supports a reproducible common-genetic susceptibility signal for Bell's palsy.
PMID:33602968 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The variant is not correlated (r2 < 0.2) with any known coding or structural variants."
This restricts the associated locus to an unresolved noncoding signal.
PMID:33602968 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"We examined cis-eQTL in blood and adipose tissue in Iceland and did not find an association between rs9357446 and expression of nearby genes (Supplementary Note)."
Negative expression analyses do not support naming a regulatory target gene.
💊

Medical Actions

9
Early oral corticosteroids in adults
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: prednisolone CHEBI:8378 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisolone (CHEBI:8378). CHEBI:8378 is a therapeutic agent from Chemical Entities of Biological Interest. prednisone CHEBI:8382 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisone (CHEBI:8382). CHEBI:8382 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Oral corticosteroids improve recovery in adults when started within 72 hours; the AAO-HNSF recommendation applies to patients aged 16 years and older. Two large placebo-controlled factorial trials support prednisolone. In the 2007 study, complete recovery at three months was 83.0% with prednisolone versus 63.6% without it, and at nine months 94.4% versus 81.6%. These are factorial comparisons, not a comparison of combination therapy with double placebo. Contraindications and individual risks still require clinical assessment.
Mechanism Target:
Facial nerve edema within the facial canal — Anti-inflammatory therapy is intended to reduce swelling; efficacy trials establish recovery benefit, not direct measurement of local nerve edema.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Prednisone and other oral corticosteroids reduce nerve swelling and may speed up the recovery of facial actions and expressions."
Review-level mechanistic rationale for corticosteroid treatment.
Show evidence (3 references)
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should prescribe oral steroids within 72 hours of symptom onset for Bell's palsy patients 16 years and older"
This provides the treatment window and age scope.
PMID:17942873 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"In patients with Bell's palsy, early treatment with prednisolone significantly improves the chances of complete recovery at 3 and 9 months."
The 551-participant randomized factorial trial supports adult steroid benefit.
PMID:18849193 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Prednisolone shortened the time to complete recovery in patients with Bell's palsy, whereas valaciclovir did not affect facial recovery."
An independent multicenter trial randomized 839 adults and analyzed 829, corroborating prednisolone benefit.
Adjunctive antiviral therapy
Action: antiviral therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antiviral therapy (NCIT:C16119). NCIT:C16119 is a clinical intervention from the NCI Thesaurus. Ontology label: Antiviral Therapy NCIT:C16119
Agent: acyclovir CHEBI:2453 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses acyclovir (CHEBI:2453). CHEBI:2453 is a therapeutic agent from Chemical Entities of Biological Interest. valacyclovir CHEBI:35854 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses valacyclovir (CHEBI:35854). CHEBI:35854 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Acyclovir or valacyclovir may be offered with corticosteroids within 72 hours, with discussion of uncertain additional recovery benefit; antiviral monotherapy is not recommended. The 2019 Cochrane analysis restricted to trials at lower risk of bias found no clear improvement in incomplete recovery (RR 0.81, 95% CI 0.38-1.74), including an imprecise severe-palsy subgroup. Combination treatment probably reduces the composite late outcome of synkinesis or crocodile tears. A small 50-patient trial reported better recovery with add-on acyclovir, but this does not override the larger trials or pooled uncertainty.
Show evidence (4 references)
PMID:31486071 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise."
The synthesis separates uncertain facial recovery benefit from sequelae reduction.
PMID:31486071 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone."
The pooled composite of motor synkinesis or crocodile tears favored combination therapy (RR 0.56, 95% CI 0.36-0.87, two trials with 469 participants); it is not a separate estimate for each component.
PMID:27689547 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"At the end of the 3rd month, 17 patients (68%) had good recovery and 8 patients (32%) had poor recovery in the steroid group compared with 23 patients (92%) and 2 (8%) respectively in the steroid and antiviral group"
The small trial reports a positive comparison that must be considered alongside larger studies and risk-of-bias-sensitive synthesis.
+ 1 more reference
Facial physical therapy
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Platform: Behavioral / lifestyle
Specialist facial neuromuscular retraining, with feedback where available, is first-line management for established synkinesis and can help persistent weakness. The aim in synkinesis is selective control of intended movements and relaxation of unintended contractions. Evidence and goals differ from acute-phase exercises; studies vary in timing, method and quality.
Target Phenotypes: Facial synkinesis HP:0034979 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Facial synkinesis (HP:0034979). HP:0034979 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Physical therapy and Botox injections can help patients with persistent symptoms."
This supports physical therapy as a symptomatic treatment for persistent Bell's palsy deficits.
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Facial training is the basis of synkinesis therapy."
International consensus places tailored training first in established synkinesis.
PMID:38517799 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Outcomes of studies with physical therapy varied, regarding recovery rate and time to recovery, although most studies showed better outcomes for physical therapy, compared to usual care."
This sentence is from the Bell's palsy subgroup of a multi-disease review, not an extrapolation from FSHD.
Botulinum toxin type A therapy
Action: botulinum toxin type A therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is botulinum toxin type A therapy, annotated with Botulinum Toxin Therapy (NCIT:C157775). NCIT:C157775 is a clinical intervention from the NCI Thesaurus. Ontology label: Botulinum Toxin Therapy NCIT:C157775
Agent: Botulinum toxin type A CHEBI:3160 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses Botulinum toxin type A (CHEBI:3160). CHEBI:3160 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Other
Specialist botulinum toxin type A injections can reduce troublesome synkinetic contractions after incomplete recovery, often alongside retraining. This is symptomatic, off-label management of established synkinesis; unintended weakness can occur through excessive dose or diffusion to adjacent muscles. It does not restore an injured facial nerve.
Target Phenotypes: facial synkinesis HP:0034979 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets facial synkinesis (HP:0034979). HP:0034979 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Physical therapy and Botox injections can help patients with persistent symptoms."
This supports botulinum toxin treatment for persistent Bell's palsy sequelae such as synkinesis and asymmetry.
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Botulinum toxin injections are an established and effective but off-label use therapy for patients with facial synkinesis worldwide"
Consensus supports symptomatic treatment of synkinesis, not treatment of the acute neuropathy.
Eye lubrication and eyelid protection
Platform: Other
Protect the cornea whenever eye closure or blinking is incomplete. Lubricating drops during the day and lubricating ointment with assisted eyelid closure at night reduce exposure. Eye pain, redness or visual symptoms require reassessment. Eye care remains necessary regardless of whether corticosteroids or antivirals are used.
Target Phenotypes: Lagophthalmos HP:0030001 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Lagophthalmos (HP:0030001). HP:0030001 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should implement eye protection for Bell's palsy patients with impaired eye closure."
Eye protection is a strong care recommendation.
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Patients with incomplete eye closure should be given eye protection, with lubricating drops and ointments, to prevent corneal damage."
This supports concrete protective measures.
Prednisolone in children: uncertain benefit
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: prednisolone CHEBI:8378 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prednisolone (CHEBI:8378). CHEBI:8378 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Adult corticosteroid efficacy should not be assumed in younger children. BellPIC randomized 187 children aged six months to under 18 years within 72 hours, rather than the planned 540. Ten days of prednisolone did not improve complete recovery at one month (49% versus 57% with placebo); the study was underpowered and cannot exclude important benefit or harm. Most children recovered by six months. Pediatric guidance therefore describes insufficient evidence for routine early prednisolone.
Show evidence (3 references)
PMID:36008143 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"This study, although underpowered, does not provide evidence that early treatment with prednisolone improves complete recovery."
Absence of demonstrated benefit in an underpowered trial is not proof of equivalence.
url:https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The results of these secondary outcomes suggest caution in interpreting the primary outcome result in isolation as evidence that prednisolone provides no clinical benefit in the management of Bell’s palsy in children."
The full manuscript explicitly cautions against an absolute no-benefit conclusion.
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"There is not enough evidence that early treatment with prednisolone improves complete recovery in children"
The pediatric guideline distinguishes child evidence from adult treatment recommendations.
Facial nerve decompression: uncertain benefit
Action: surgical decompression of the facial nerveNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical decompression of the facial nerve, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Surgery
Decompression has been studied for severe paralysis with substantial electrophysiologic degeneration but is not routine care. Canadian guidance recommends against routine decompression because evidence is weak and surgery can cause hearing loss, further nerve injury or cerebrospinal fluid leak. A retrospective comparison of 15 operated and 30 conservatively treated severe cases found no significant added benefit from transmastoid surgery at 21-70 days. It does not establish whether other surgical timing or approaches benefit selected patients.
Show evidence (2 references)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"We suggest against the routine use of surgical decompression."
The guideline recommendation reflects uncertain benefit and operative risks.
PMID:35160337 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Although we found that surgical decompression (performed 21–70 days after symptom onset) in severe Bell’s palsy improved functional outcomes, the functional improvement was not statistically different from that of the control group at the 6-month follow-up."
The controlled observational comparison does not show added benefit; spontaneous recovery and treatment selection constrain inference.
Intratympanic dexamethasone: investigational
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dexamethasone CHEBI:41879 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dexamethasone (CHEBI:41879). CHEBI:41879 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Local dexamethasone injection has been studied as an adjunct or alternative when oral steroids cannot be given. NCT03508440 is a completed phase II/III study with only ten participants: one received oral steroids alone, nine received oral steroids plus injection, and none received injection alone. This extreme imbalance does not establish comparative efficacy.
Show evidence (2 references)
clinicaltrials:NCT03508440 SUPPORT DIRECT BACKGROUND Other
"There are indications that the use of intratympanic injections, in addition to the oral steroids, will speed up the recovery rate of the facial nerve paralysis, as well as improve the complete recovery of the facial nerve paralysis."
This is the registered rationale, not an efficacy result.
url:https://clinicaltrials.gov/api/v2/studies/NCT03508440 SUPPORT DIRECT PRIMARY RESULT Other
"Injection only was for participants who could not, for medical reasons, receive the SOC treatment. We did not have any patients that met that criteria ... "type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"}]"
The participant-flow groups are oral standard care, standard care plus injection and injection alone, respectively. The extreme imbalance precludes a reliable comparative treatment estimate.
Laser acupuncture and photobiomodulation: investigational
Action: Photobiomodulation TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Photobiomodulation Therapy (NCIT:C21063). NCIT:C21063 is a clinical intervention from the NCI Thesaurus. NCIT:C21063
Platform: Device
A single-center randomized trial in 84 adults with persistent palsy reported better facial grading and electrophysiologic outcomes with combined laser acupuncture/photobiomodulation than with lower-intensity laser exposure. Treating physicians were unblinded and the comparator delivered laser energy. Inconsistent duration and follow-up reporting and lack of independent replication limit interpretation; this is not established routine treatment or evidence for a specific molecular mechanism. The trial excluded complete paralysis and marked electrophysiologic degeneration, limiting applicability to the most severe cases.
Show evidence (3 references)
PMID:38216803 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The findings of this randomized controlled trial, single-center study suggest that laser acupuncture and photobiomodulation therapy relieve symptoms for patients with Bell’s palsy over 8 weeks."
The study reports clinical improvement in persistent palsy, with design and reporting limitations.
PMID:38216803 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The study patients and data analysts were blinded to intervention assignment, but the physicians were not blinded."
Unblinded treating clinicians constrain confidence in a single-center study.
PMID:38216803 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The control group received the same Multiwave Locked System device, same points in affected face and acupoints."
The comparator was a lower-energy active device setting rather than a laser-off sham.
🔬

Diagnosis

5
Clinical history and neurologic physical examination
Diagnosis requires acute peripheral facial weakness and a focused history, full neurologic examination, ear/skin examination and assessment of eye closure. Forehead involvement supports a peripheral pattern but is not sufficient to exclude every stroke. Typical new-onset Bell's palsy does not require routine laboratory tests or imaging; targeted investigation follows exposure history, systemic signs, progression or other atypical findings.
physical examination NCIT:C20989 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
This directly supports diagnosis by focused clinical evaluation and exclusion of key mimics.
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should not obtain routine laboratory testing in patients with new-onset Bell's palsy"
The recommendation applies to a typical clinical presentation, not to a patient with features suggesting another cause.
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should not routinely perform diagnostic imaging for patients with new-onset Bell's palsy"
Routine imaging is unnecessary in otherwise typical new-onset disease.
Selective electromyography
AAO-HNSF guidance advises against electrodiagnostic testing for typical incomplete facial paresis and permits it in complete paralysis. Needle EMG can assess axonal degeneration, reinnervation and established synkinesis; denervation changes may not appear until 10-14 days, with testing most informative from about two to three weeks. The 2020 international electrodiagnostic guideline notes that some national guidelines recommend broader testing.
electromyography procedure NCIT:C38056 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should not perform electrodiagnostic testing in Bell's palsy patients with incomplete facial paralysis"
This prevents routine EMG recommendations based only on a trial's testing protocol.
PMID:32270328 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Signs of muscle degeneration cannot be seen by EMG before 10–14 days."
An early normal EMG does not exclude evolving axonal injury.
PMID:32270328 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"In contrast, the German and the Spanish guidelines recommend electrodiagnostics for all patients with Bell’s palsy"
Specialty guidance differs on the breadth of testing; the AAO-HNSF recommendation is identified by source.
Electroneuronography in complete paralysis
Electroneuronography compares evoked facial-muscle responses between affected and unaffected sides to estimate degeneration. In complete palsy it can inform prognosis, interpreted together with EMG and clinical severity. Responses may remain normal during the first 72 hours; the useful acute window is approximately 72 hours to 21 days. Severe degeneration is a prognostic finding, not proof that decompression surgery will improve outcome.
nerve conduction study NCIT:C88502 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:32270328 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"ENoG can show completely normal results during this 72-h window."
Wallerian degeneration has not necessarily reached the distal stimulation segment immediately after an intratemporal lesion.
PMID:32270328 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"ENoG is most valuable within the time window of 72 h to 21 days after onset of the lesion."
The guideline provides the timing needed for interpreting this prognostic test.
Facial function and synkinesis grading
House-Brackmann and Sunnybrook scores document baseline severity and recovery. For persistent synkinesis, Sunnybrook or eFACE assessment and the Synkinesis Assessment Questionnaire capture clinician and patient perspectives; a global facial score alone can miss the pattern or impact of involuntary movements.
Show evidence (2 references)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Commonly used facial grading instruments (e,g., House–Brackmann and Sunnybrook scales) quantify the severity of facial weakness."
Standardized grading documents severity rather than replacing etiologic diagnosis.
PMID:36438936 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The Synkinesis Assessment Questionnaire (SAQ) is a specific PROM for the evaluation of synkinesis"
A dedicated patient-reported measure complements facial movement examination.
Reassessment and targeted imaging for atypical or persistent palsy
Reassess or refer for new or worsening neurologic findings, ocular symptoms at any time, or incomplete facial recovery at three months. Persistent progressive weakness requires evaluation along the facial nerve course for structural causes, using specialist-directed MRI or high-resolution CT as appropriate. This is distinct from routine imaging of typical acute Bell's palsy.
Show evidence (2 references)
PMID:24189771 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"clinicians should reassess or refer to a facial nerve specialist those Bell's palsy patients with (1) new or worsening neurologic findings at any point, (2) ocular symptoms developing at any point, or (3) incomplete facial recovery 3 months after initial symptom onset."
The guideline defines concrete reassessment triggers.
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"We recommend imaging to rule out neoplasms or alternative diagnoses for patients with no improvement or progressive weakness."
Persistent or progressive dysfunction changes the investigation threshold.
📈

Progression

2
Acute onset phase
Facial weakness typically appears suddenly and progresses to maximal deficit over the first 48 hours.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Bell's palsy, also known as "acute facial palsy of unknown cause", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
This supports the typical abrupt onset and short early progression window.
Recovery and sequelae phase
Recovery develops over weeks to months and varies with initial severity. Early improvement is distinct from complete recovery. Adult trials assess complete recovery at three to twelve months; in the pediatric BellPIC trial, 57% of placebo recipients had complete recovery at one month and 93% at six months. Persistent weakness, synkinesis and psychosocial distress can remain. These trial-specific estimates should not be generalized to every age or severity group.
Show evidence (3 references)
PMID:36008143 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"At 1 month, the proportions of patients who had recovered facial function were 49% (n = 43/87) in the prednisolone group compared with 57% (n = 50/87) in the placebo group"
The pediatric trial distinguishes one-month recovery from later improvement.
PMID:37752723 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Bell's palsy, myotonic dystrophy type 1, and Parkinson's disease patients more often experienced some degree of psychosocial distress than healthy controls."
The Bell's palsy subgroup supports psychosocial morbidity without assigning a psychiatric diagnosis or prevalence.
PMID:34640384 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Our results showed that the most important factor influencing the complete recovery of Bell's palsy in children was the lower initial H-B grade at initial presentation."
The 88-child retrospective cohort associated milder initial palsy with recovery; its nonrandomized treatment comparisons do not establish treatment efficacy.
📊

Prevalence

1
General population
Annual Incidence 20.0–30.0 per 100,000 per year 1–9 per 10,000 per year
Bell's palsy is relatively common among cranial mononeuropathies, with modern review literature consistently citing an annual incidence around 20-30 cases per 100,000 people.
Show evidence (1 reference)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The annual incidence is 20 to 30 per 100,000."
This provides a direct contemporary incidence estimate for Bell's palsy in the general population.
🌍

Epidemiology

3
Age and clinical risk-factor distribution
Bell's palsy can occur at any age, but incidence rises with age and is increased in people with diabetes, hypertension, obesity, pregnancy, and recent upper respiratory tract infection.
age diabetes hypertension pregnancy obesity upper respiratory tract infection
Show evidence (2 references)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Both sexes are equally affected, and though no age is immune, its incidence rises with increasing age."
This supports the age distribution of Bell's palsy as a disorder that can occur broadly but becomes more common with increasing age.
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"The risk is high in diabetics, hypertensives, women who are pregnant, obese, and people with upper respiratory tract infections."
This supports several commonly cited clinical risk groups and comorbidity associations.
Migraine-associated risk enrichment
A Korean insurance cohort associated migraine with a small increase in subsequent Bell's palsy risk: adjusted hazard ratio 1.16 (95% CI 1.01-1.33). Administrative diagnoses and treatment-based case selection do not establish a causal effect of migraine. The publication's abstract gives an inconsistent P value, so the effect estimate and confidence interval are the interpretable summary.
migraine
Show evidence (1 reference)
PMID:31124964 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"The adjusted HR of Bell palsy was 1.16 in the migraine group compared with the control group"
This is a modest observational association in matched insurance records, not proof of a shared causal mechanism.
Recurrence burden
Recurrence is recognized in a minority of patients. Published estimates vary; a narrative review summarizes a 4-14% range. Recurrent or otherwise atypical palsy warrants reconsideration of alternative diagnoses.
Show evidence (1 reference)
PMID:36397921 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Four to 14 percent of patients may experience recurrence, with 36 percent suffering from palsy on the same side"
This is a review-level range, not a uniform prospective recurrence estimate.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Bell's palsy:

Stroke Not Yet Curated MONDO:0005098
Overlapping Features Acute facial weakness from stroke can mimic Bell's palsy, but Bell's palsy produces a peripheral facial weakness pattern and is diagnosed only after alternative causes are excluded.
Distinguishing Features
  • Typical Bell's palsy affects the upper and lower ipsilateral face. Forehead sparing suggests a supranuclear lesion, but forehead involvement alone cannot exclude a brainstem lesion.
  • Additional limb weakness, ataxia, diplopia or other neurologic deficits require urgent evaluation for an alternative diagnosis.
Show evidence (2 references)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
This directly supports stroke as an important alternative diagnosis that must be excluded.
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Other neurological features such as severe headache, blurred vision, double vision, weakness/numbness in arms or extremities, ataxia"
Associated neurologic signs are red flags rather than part of uncomplicated Bell's palsy.
Lyme disease MONDO:0019632
Overlapping Features Lyme neuroborreliosis can present with acute facial palsy and should be considered in the appropriate epidemiologic setting.
Distinguishing Features
  • Lyme disease is suggested by tick exposure, compatible geography, systemic symptoms, or other evidence of Borrelia infection.
  • Bell's palsy remains idiopathic after focused evaluation and exclusion of alternative infectious causes.
Show evidence (1 reference)
PMID:39939082 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
This directly supports Lyme disease as a clinically important differential diagnosis for Bell's palsy.
Melkersson-Rosenthal syndrome MONDO:0007969
Overlapping Features Melkersson-Rosenthal syndrome can include facial paralysis, but it is distinguished by recurrent disease together with lip or facial edema and a fissured tongue.
Distinguishing Features
  • Melkersson-Rosenthal syndrome includes additional recurrent orofacial edema and fissured tongue rather than isolated acute idiopathic facial weakness.
  • Bell's palsy is typically an isolated acute peripheral facial palsy without the classic granulomatous syndrome features.
Show evidence (1 reference)
PMID:40255708 SUPPORT DIRECT BACKGROUND Human Clinical
"CG can occur as an isolated condition or as part of Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue."
The case-report background describes the Melkersson-Rosenthal syndrome triad; the reported patient did not establish a Bell's palsy mechanism.
Ramsay Hunt syndrome and other otologic causes
Overlapping Features Varicella-zoster-associated peripheral facial palsy, otitis media, mastoiditis and other ear disease require a different etiologic diagnosis. Ear or oral vesicles, severe otalgia, hearing or vestibular symptoms, or abnormal otoscopy should prompt targeted assessment.
Distinguishing Features
  • Ramsay Hunt syndrome can produce ear-canal or facial vesicles with peripheral facial palsy.
  • Severe pain or local ear findings favor a specific otologic or infectious cause over uncomplicated idiopathic palsy.
Show evidence (2 references)
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Skin lesions or vesicles on the face or in the ear canal (Ramsay Hunt Syndrome)"
The pediatric guideline identifies vesicles as a discriminator.
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Severe pain (may indicate mastoiditis, VZV)"
Severe otalgia is a red flag for an alternative otologic or infectious cause.
Structural facial nerve lesions
Overlapping Features Facial nerve schwannoma, skull-base neoplasm or parotid pathology may cause progressive or nonrecovering facial weakness. Persistent progression requires reassessment and imaging rather than indefinite attribution to Bell's palsy.
Distinguishing Features
  • Progressive weakness or failure to improve prompts investigation of the facial nerve course.
Show evidence (1 reference)
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Referral to a specialist may avoid missed diagnoses of malignant skull-base neoplasms"
The guideline highlights structural mimics in patients who fail to improve.
🔬

Clinical Trials

6
NCT03508440 PHASE_III COMPLETED
Completed phase II/III intratympanic dexamethasone study in acute moderate-to-severe palsy. The posted results include ten participants: one on oral steroids alone and nine on oral steroids plus injection; no participant received injection alone. Reported mean recovery times cannot establish comparative efficacy with a single control participant.
Target Phenotypes: facial weakness HP:0030319 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets facial weakness, annotated with Weakness of facial musculature (HP:0030319). HP:0030319 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
clinicaltrials:NCT03508440 SUPPORT DIRECT BACKGROUND Other
"There are indications that the use of intratympanic injections, in addition to the oral steroids, will speed up the recovery rate of the facial nerve paralysis, as well as improve the complete recovery of the facial nerve paralysis."
This ClinicalTrials.gov record supports a Bell's palsy trial evaluating adjunct intratympanic steroid therapy to improve recovery.
url:https://clinicaltrials.gov/api/v2/studies/NCT03508440 SUPPORT DIRECT PRIMARY RESULT Other
"Injection only was for participants who could not, for medical reasons, receive the SOC treatment. We did not have any patients that met that criteria ... "type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"}]"
The participant-flow groups are oral standard care, standard care plus injection and injection alone, respectively. The extreme imbalance precludes a reliable comparative treatment estimate.
NCT05846217 NOT_APPLICABLE COMPLETED
Completed randomized single-center trial of combined laser acupuncture/photobiomodulation for persistent palsy, with 84 randomized adults and lower-intensity laser settings as comparator. The linked publication reports better facial scores but contains inconsistent timing and disease-duration statements; it does not establish a standard treatment regimen.
Target Phenotypes: facial weakness HP:0030319 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets facial weakness, annotated with Weakness of facial musculature (HP:0030319). HP:0030319 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
clinicaltrials:NCT05846217 SUPPORT DIRECT BACKGROUND Other
"OBJECTIVE: To determine whether photobiomodulation therapy by class IV Multiwave Locked System laser treatment could relieve symptoms in patients with Bell's palsy with a duration of greater than 8 weeks."
This ClinicalTrials.gov record supports an interventional trial for persistent Bell's palsy symptoms using photobiomodulation therapy.
PMID:38216803 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"A total of 84 participants were included (42 control group, 42 laser acupuncture group)."
The registered study has published results, with reporting limitations described in the treatment entry.
NCT02328079 NOT_APPLICABLE COMPLETED
Fifty-patient randomized study of steroid alone versus steroid plus antiviral in moderately severe to complete acute palsy, published in 2016. The paper reports greater recovery with combination therapy at three months. ClinicalTrials.gov lists unmasked allocation whereas the publication describes double blinding; this unresolved discrepancy and small sample size limit certainty.
Show evidence (2 references)
PMID:27689547 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Fifty eligible patients out of a total of 65 with acute onset Bell's palsy were randomized to receive the two treatments."
This is the small positive trial; it is not a substitute for the larger placebo-controlled evidence.
PMID:27689547 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"This study was registered with ClinicalTrials.gov, number NCT02328079."
The publication explicitly links the clinical result to the registration.
NCT00510263 PHASE_IV COMPLETED
Scandinavian factorial placebo-controlled study of prednisolone and valaciclovir in adults aged 18-75 years presenting within 72 hours. Of 839 randomized patients, 829 were analyzed. Prednisolone shortened time to complete recovery; valaciclovir did not. Follow-up lasted twelve months.
Show evidence (2 references)
clinicaltrials:NCT00510263 SUPPORT DIRECT BACKGROUND Other
"The main objective of this study is to study the effects of prednisolone and valaciclovir, with equal importance, compared to placebo for the treatment of Bell´s palsy."
The registry establishes the factorial study question; efficacy is supported by the publication.
PMID:18849193 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"Prednisolone shortened the time to complete recovery in patients with Bell's palsy, whereas valaciclovir did not affect facial recovery."
The trial's published outcome supports steroids and reports no valaciclovir recovery effect.
ACTRN12615000563561 PHASE_III
BellPIC compared ten days of prednisolone with placebo in children aged six months to under 18 years presenting within 72 hours. The published trial randomized 187 of the intended 540 children and did not show improved complete recovery at one month. The uncertainty around longer-term effects must be retained.
Show evidence (2 references)
ICTRP:ACTRN12615000563561 SUPPORT DIRECT Other
"Participants assigned to the intervention will receive 1mg/kg/day of prednisolone (dosing is based on weight categories) up to a maximum of 50mg/day for 10 days."
The registry confirms the intervention and registration identity, not efficacy.
PMID:36008143 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"This study, although underpowered, does not provide evidence that early treatment with prednisolone improves complete recovery."
The published randomized trial is the source for the outcome.
ISRCTN71548196 COMPLETED
Scottish 2-by-2 factorial trial of prednisolone, acyclovir, both or double placebo within 72 hours. It randomized 551 patients and obtained final outcomes for 496. Prednisolone improved complete recovery at three and nine months; acyclovir added no demonstrated recovery benefit.
Show evidence (2 references)
ICTRP:ISRCTN71548196 SUPPORT DIRECT Other
"Inclusion criteria: Adults (16 or older) diagnosed with Bell's Palsy and with no excluding conditions and who can be consented at participating centres in Scotland within 72 hours of onset."
The registration defines the adult population and treatment window.
PMID:17942873 SUPPORT DIRECT PRIMARY RESULT Human Clinical
"There is no evidence of a benefit of acyclovir given alone or an additional benefit of acyclovir in combination with prednisolone."
The trial separates the prednisolone effect from the lack of demonstrated antiviral recovery benefit.
🐁

Animal Models

1
Mechanical facial nerve crush in Sprague-Dawley rats
Adult male rats underwent unilateral facial nerve crush near the stylomastoid foramen (50 g for 90 seconds), with sham surgery as control. Facial motor nuclei were sampled at 30 days for single-cell analysis; SLIT2 expression was also examined by tissue immunofluorescence. This is an injury-and-repair analogue, not an etiologic model of idiopathic Bell's palsy.
Species
Rattus norvegicus
Publication
PMID:41099890
Pathograph links
Facial nerve axonal injury partially recapitulates fidelity: low Mechanical nerve crush produces a peripheral injury with a subsequent central facial-nucleus response.
Limitations: Unknown human initiating etiology, peripheral inflammatory anatomy and species-specific motor-nucleus biology are not reproduced. No targeted rescue of SLIT2 signaling was tested.
Show evidence (1 reference)
PMID:41099890 SUPPORT DIRECT PRIMARY RESULT Model Organism
"A custom-made stainless-steel peripheral nerve clamp was used to damage the main trunk of the facial nerve. The clamp was applied with a pressure of 50 g for 90 s"
The intervention is mechanical nerve injury, not viral reactivation or spontaneous Bell's palsy.
Cell-type expression, inferred ligand-receptor communication and pseudotime do not demonstrate temporal lineage transitions or functional rescue. The paper did not intervene on SLIT2 or ROBO, and the response was measured in the central facial nucleus rather than the peripheral lesion.
Show evidence (1 reference)
PMID:41099890 SUPPORT DIRECT PRIMARY RESULT Model Organism
"A custom-made stainless-steel peripheral nerve clamp was used to damage the main trunk of the facial nerve. The clamp was applied with a pressure of 50 g for 90 s"
The intervention is mechanical nerve injury, not viral reactivation or spontaneous Bell's palsy.
{ }

Source YAML

click to show 
name: Bell's palsy
creation_date: "2026-03-18T15:33:50Z"
category: Complex
categories:
- Neurological Disease
- Cranial Neuropathy
description: >-
  Bell's palsy is an acute idiopathic peripheral facial neuropathy, usually producing unilateral weakness of
  the upper and lower face. Inflammatory swelling and compression of cranial nerve VII in the facial canal
  form the leading mechanistic model, while the initiating cause remains uncertain. Viral reactivation and
  common genetic susceptibility are proposed contributors. Most patients improve over weeks to months, but
  axonal injury can leave persistent weakness or synkinesis.
disease_term:
  preferred_term: Bell's palsy
  term:
    id: MONDO:0005665
    label: Bell's palsy
synonyms:
- idiopathic peripheral facial palsy
- idiopathic facial nerve palsy
definitions:
- name: Clinical syndrome definition for Bell's palsy
  definition_type: CASE_DEFINITION
  description: >-
    Acute unilateral peripheral facial weakness or paralysis of unknown cause after clinical exclusion of alternative
    etiologies; weakness develops rapidly, usually over hours to two days.
  scope: General clinical framing of acute idiopathic peripheral facial palsy
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bell's palsy is acute weakness of the facial muscles associated with compression of cranial nerve VII."
    explanation: This directly supports the standard clinical definition of Bell's palsy as acute cranial-nerve-VII-mediated facial weakness.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bell's palsy, also known as \"acute facial palsy of unknown cause\", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
    explanation: This supports the idiopathic acute cranial-neuropathy framing and typical time course.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:G51.0
      label: Bell's palsy
    mapping_predicate: skos:exactMatch
    mapping_source: ICD-10-CM
    mapping_justification: Bell's palsy is represented directly by ICD-10-CM code G51.0.
  mondo_mappings:
  - term:
      id: MONDO:0005665
      label: Bell's palsy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this Bell's palsy entry.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:39939082
      reference_title: "Bell's Palsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Bell's palsy is acute weakness of the facial muscles associated with compression of cranial nerve VII."
      explanation: This supports classification of Bell's palsy as a nervous system disorder centered on cranial nerve VII dysfunction.
      directness: DIRECT
      quote_role: REVIEW_SYNTHESIS
parents:
- Neurological Disorder
- Peripheral Neuropathy
prevalence:
- population: General population
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 20.0
  rate_high: 30.0
  notes: >-
    Bell's palsy is relatively common among cranial mononeuropathies, with
    modern review literature consistently citing an annual incidence around
    20-30 cases per 100,000 people.
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The annual incidence is 20 to 30 per 100,000."
    explanation: This provides a direct contemporary incidence estimate for Bell's palsy in the general population.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  rate_denominator: POPULATION_PER_YEAR
epidemiology:
- name: Age and clinical risk-factor distribution
  description: >-
    Bell's palsy can occur at any age, but incidence rises with age and is
    increased in people with diabetes, hypertension, obesity, pregnancy, and
    recent upper respiratory tract infection.
  factors:
  - age
  - diabetes
  - hypertension
  - pregnancy
  - obesity
  - upper respiratory tract infection
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both sexes are equally affected, and though no age is immune, its incidence rises with increasing age."
    explanation: This supports the age distribution of Bell's palsy as a disorder that can occur broadly but becomes more common with increasing age.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk is high in diabetics, hypertensives, women who are pregnant, obese, and people with upper respiratory tract infections."
    explanation: This supports several commonly cited clinical risk groups and comorbidity associations.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Migraine-associated risk enrichment
  description: >-
    A Korean insurance cohort associated migraine with a small increase in subsequent Bell's palsy risk: adjusted
    hazard ratio 1.16 (95% CI 1.01-1.33). Administrative diagnoses and treatment-based case selection do not
    establish a causal effect of migraine. The publication's abstract gives an inconsistent P value, so the
    effect estimate and confidence interval are the interpretable summary.
  factors:
  - migraine
  evidence:
  - reference: PMID:31124964
    reference_title: 'Increased risk of Bell palsy in patient with migraine: A longitudinal follow-up study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The adjusted HR of Bell palsy was 1.16 in the migraine group compared with the control group
    explanation: >-
      This is a modest observational association in matched insurance records, not proof of a shared causal
      mechanism.
    quote_role: PRIMARY_RESULT
- name: Recurrence burden
  description: >-
    Recurrence is recognized in a minority of patients. Published estimates vary; a narrative review summarizes
    a 4-14% range. Recurrent or otherwise atypical palsy warrants reconsideration of alternative diagnoses.
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Four to 14 percent of patients may experience recurrence, with 36 percent suffering from palsy on the
      same side
    explanation: >-
      This is a review-level range, not a uniform prospective recurrence estimate.
    quote_role: REVIEW_SYNTHESIS
progression:
- phase: Acute onset phase
  notes: >-
    Facial weakness typically appears suddenly and progresses to maximal
    deficit over the first 48 hours.
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bell's palsy, also known as \"acute facial palsy of unknown cause\", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
    explanation: This supports the typical abrupt onset and short early progression window.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- phase: Recovery and sequelae phase
  notes: >-
    Recovery develops over weeks to months and varies with initial severity. Early improvement is distinct
    from complete recovery. Adult trials assess complete recovery at three to twelve months; in the pediatric
    BellPIC trial, 57% of placebo recipients had complete recovery at one month and 93% at six months. Persistent
    weakness, synkinesis and psychosocial distress can remain. These trial-specific estimates should not be
    generalized to every age or severity group.
  evidence:
  - reference: PMID:36008143
    reference_title: 'Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      At 1 month, the proportions of patients who had recovered facial function were 49% (n = 43/87) in the
      prednisolone group compared with 57% (n = 50/87) in the placebo group
    explanation: >-
      The pediatric trial distinguishes one-month recovery from later improvement.
    quote_role: PRIMARY_RESULT
  - reference: PMID:37752723
    reference_title: 'Psychosocial functioning in patients with altered facial expression: a scoping review in five neurological diseases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Bell's palsy, myotonic dystrophy type 1, and Parkinson's disease patients more often experienced some
      degree of psychosocial distress than healthy controls.
    explanation: >-
      The Bell's palsy subgroup supports psychosocial morbidity without assigning a psychiatric diagnosis or
      prevalence.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:34640384
    reference_title: Clinical Prognostic Factors Associated with Good Outcomes in Pediatric Bell's Palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Our results showed that the most important factor influencing the complete recovery of Bell's palsy in
      children was the lower initial H-B grade at initial presentation.
    explanation: >-
      The 88-child retrospective cohort associated milder initial palsy with recovery; its nonrandomized treatment
      comparisons do not establish treatment efficacy.
    quote_role: PRIMARY_RESULT
pathophysiology:
- name: Putative herpesvirus reactivation
  description: >-
    Reactivation of latent HSV-1 is one proposed initiating event, not an established cause in every idiopathic
    case. A small prospective study detected HSV-1 DNA in endoneurial fluid or posterior auricular muscle from
    11 of 14 Bell's palsy patients, compared with none of nine Ramsay Hunt patients and twelve other controls.
    Detection in selected clinical samples supports the hypothesis but does not establish timing, causal sufficiency
    or population prevalence.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:7503474
    reference_title: 'Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not
      in patients with the Ramsay-Hunt syndrome or in other controls.
    explanation: >-
      This human molecular observation is evidence for a viral hypothesis, not proof that all Bell's palsy
      is infectious.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Facial nerve inflammation
    description: >-
      Proposed viral initiation of local inflammation; causality is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
      reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        The major cause of Bell palsy is believed to be an infection of the facial nerve by the herpes simplex
        virus.
      explanation: >-
        The phrase 'believed' denotes an etiologic model; the small PCR study supports, but does not settle,
        that model.
      quote_role: REVIEW_SYNTHESIS
    hypothesis_groups:
    - VIRAL_REACTIVATION
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Facial nerve inflammation
  description: >-
    Local inflammation around the facial nerve is a leading explanatory process. The initiating event and relative
    contributions of viral reactivation, immune responses and vascular factors remain unresolved.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:33602968
    reference_title: A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      While the pathogenesis remains unknown, previous studies have implicated post-viral inflammation and
      resulting compression of the facial nerve.
    explanation: >-
      The GWAS introduction summarizes the inflammatory model rather than experimentally demonstrating it.
    quote_role: BACKGROUND
  downstream:
  - target: Facial nerve edema within the facial canal
    description: >-
      Inflammatory injury is modeled as upstream of swelling.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33602968
      reference_title: A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        While the pathogenesis remains unknown, previous studies have implicated post-viral inflammation and
        resulting compression of the facial nerve.
      explanation: >-
        Indirect review-level support for swelling in the inflammatory model.
      quote_role: BACKGROUND
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
- name: Facial nerve edema within the facial canal
  description: >-
    Swelling of the facial nerve within the narrow bony facial canal limits its ability to expand. This is
    the proposed anatomical substrate for secondary compression.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:35160337
    reference_title: Comparison of Medical and Surgical Treatment in Severe Bell's Palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The pathophysiology of Bell’s palsy includes edematous swelling of the facial nerve within the Fallopian
      canal, which causes a conduction block and subsequent dysfunction.
    explanation: >-
      The surgical study's background summarizes the anatomical model; its operative comparison is separate
      evidence.
    quote_role: BACKGROUND
  downstream:
  - target: Facial nerve compression
    description: >-
      Swelling within a confined canal produces local compression.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
      reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        As a result of this viral infection, the facial nerve swells and is compressed in its canal as it courses
        through the temporal bone.
      explanation: >-
        The guideline describes compression in a proposed viral-inflammatory model; the viral antecedent is
        not independently proven by this review.
      quote_role: REVIEW_SYNTHESIS
  - target: Facial nerve axonal injury
    description: >-
      More severe inflammatory lesions may include axonal degeneration.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34640384
      reference_title: Clinical Prognostic Factors Associated with Good Outcomes in Pediatric Bell's Palsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        It can be caused by inflammation and edema of the facial nerve fibers, with infiltration of lymphocytes
        and associated demyelination or axonal degeneration
      explanation: >-
        This is background synthesis in a pediatric cohort, not direct histologic evidence from that cohort.
      quote_role: BACKGROUND
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Facial nerve compression
  description: >-
    The rigid intratemporal canal constrains a swollen facial nerve, producing local compression, particularly
    at narrow segments. Anatomical compression is distinct from the resulting conduction failure and from axonal
    degeneration.
  biological_scale: TISSUE
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      As a result of this viral infection, the facial nerve swells and is compressed in its canal as it courses
      through the temporal bone.
    explanation: >-
      The guideline describes compression in a proposed viral-inflammatory model; the viral antecedent is not
      independently proven by this review.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Facial nerve conduction impairment
    description: >-
      Local mechanical constraint can impair nerve conduction.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35160337
      reference_title: Comparison of Medical and Surgical Treatment in Severe Bell's Palsy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        The pathophysiology of Bell’s palsy includes edematous swelling of the facial nerve within the Fallopian
        canal, which causes a conduction block and subsequent dysfunction.
      explanation: >-
        The surgical study's background summarizes the anatomical model; its operative comparison is separate
        evidence.
      quote_role: BACKGROUND
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Facial nerve conduction impairment
  description: >-
    Reduced conduction through affected facial nerve fibers produces lower motor neuron facial weakness and
    can disturb facial-nerve-associated taste, stapedius function and tear secretion. In neurapraxia, conduction
    block occurs without axonal disruption and can recover without the regeneration required for synkinesis.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Many patients with Bell's palsy fortunately only develop neurapraxia, i.e., a transient blockage of facial
      nerve conduction without axonal damage
    explanation: >-
      This explicitly distinguishes reversible conduction block from axonal injury.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Facial weakness
    description: >-
      Impaired motor output weakens the facial musculature.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Symptoms of Bell's palsy include the inability to blink or close the eye, ruck up the lips or raise
        the mouth corner
      explanation: >-
        The review describes motor manifestations of peripheral facial nerve dysfunction.
      quote_role: REVIEW_SYNTHESIS
  - target: Lagophthalmos
    description: >-
      Orbicularis oculi weakness prevents complete eyelid closure.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Symptoms of Bell's palsy include the inability to blink or close the eye, ruck up the lips or raise
        the mouth corner
      explanation: >-
        The review describes motor manifestations of peripheral facial nerve dysfunction.
      quote_role: REVIEW_SYNTHESIS
  - target: Abnormal taste sensation
    description: >-
      Associated taste-fiber dysfunction alters taste sensation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
        in taste, and dry eyes caused by parasympathetic affliction.
      explanation: >-
        Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
      quote_role: REVIEW_SYNTHESIS
  - target: Hyperacusis
    description: >-
      Stapedius pathway dysfunction reduces normal sound attenuation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
        in taste, and dry eyes caused by parasympathetic affliction.
      explanation: >-
        Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
      quote_role: REVIEW_SYNTHESIS
  - target: Dry eyes
    description: >-
      Parasympathetic involvement can reduce tear secretion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
        in taste, and dry eyes caused by parasympathetic affliction.
      explanation: >-
        Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
      quote_role: REVIEW_SYNTHESIS
  - target: Ocular surface exposure
    description: >-
      Impaired blink and eyelid closure expose the ocular surface.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
      reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Failure to protect the cornea among patients who are unable to blink adequately may result in corneal
        ulceration and permanent visual impairment.
      explanation: >-
        The guideline directly links inadequate protection in impaired blinking with corneal complications.
      quote_role: REVIEW_SYNTHESIS
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
  cell_types:
  - preferred_term: peripheral nervous system neuron
    term:
      id: CL:2000032
      label: peripheral nervous system neuron
- name: Facial nerve axonal injury
  description: >-
    More severe lesions include axonal degeneration rather than isolated neurapraxia. Wallerian degeneration
    reaches distal segments after a delay, explaining why early distal electrical responses may remain intact.
    Axonal injury increases the possibility of incomplete recovery and creates the substrate for abnormal reinnervation.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Only those patients with Bell's palsy and axonal damage can develop facial synkinesis.
    explanation: >-
      The synkinesis review identifies axonal damage as a prerequisite, not a universal feature of Bell's palsy.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Misguided facial motor axon regeneration
    description: >-
      Regeneration after axonal injury may be misdirected; this does not occur after pure neurapraxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36438936
      reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        The synkinesis is a result of misguided nerve regeneration following axonal damage.
      explanation: >-
        This supports aberrant regeneration as the principal explanatory process for synkinesis.
      quote_role: REVIEW_SYNTHESIS
  - target: Misdirected secretomotor reinnervation of the lacrimal gland
    description: >-
      Abnormal reinnervation after a proximal facial nerve lesion may involve autonomic as well as motor fibers.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36438936
      reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Another rare symptom is gustatory hyperlacrimation (crocodile tears) induced by misdirected reinnervation
        of gustatory fibers through the greater superficial petrosal nerve to reach the lacrimal gland. This
        results in tearing when the patient eats (38).
      explanation: >-
        The review describes gustatory tearing as an autonomic sequela of misdirected reinnervation.
      quote_role: REVIEW_SYNTHESIS
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Misguided facial motor axon regeneration
  description: >-
    Regenerating motor axons may send collateral sprouts into inappropriate facial nerve branches, coupling
    muscles that should move independently. This established regeneration model explains post-paralytic synkinesis;
    ephaptic transmission and central remodeling are additional proposed contributors with different levels
    of evidence.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The synkinesis is a result of misguided nerve regeneration following axonal damage.
    explanation: >-
      This supports aberrant regeneration as the principal explanatory process for synkinesis.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Facial synkinesis occurs when one axon sends sprouts to muscle fibers of two different muscles, i.e.,
      the original target muscle and any other muscle.
    explanation: >-
      The full text describes the specific branching error rather than inferring regeneration from a drug trial.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Facial synkinesis
    description: >-
      Collateral innervation couples intended and unintended facial movements.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36438936
      reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Facial synkinesis occurs when one axon sends sprouts to muscle fibers of two different muscles, i.e.,
        the original target muscle and any other muscle.
      explanation: >-
        The full text describes the specific branching error rather than inferring regeneration from a drug
        trial.
      quote_role: REVIEW_SYNTHESIS
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Misdirected secretomotor reinnervation of the lacrimal gland
  description: >-
    Aberrant reinnervation can redirect meal-associated secretomotor output to the lacrimal gland through the
    greater superficial petrosal nerve. This autonomic miswiring produces gustatory tearing and is distinct
    from motor-axon branching into facial muscles.
  biological_scale: TISSUE
  evidence:
  - &id001
    reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Another rare symptom is gustatory hyperlacrimation (crocodile tears) induced by misdirected reinnervation
      of gustatory fibers through the greater superficial petrosal nerve to reach the lacrimal gland. This
      results in tearing when the patient eats (38).
    explanation: >-
      The review describes gustatory tearing as an autonomic sequela of misdirected reinnervation.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Gustatory lacrimation
    description: >-
      Eating triggers tearing through the misdirected secretomotor connection.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36438936
      reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Another rare symptom is gustatory hyperlacrimation (crocodile tears) induced by misdirected reinnervation
        of gustatory fibers through the greater superficial petrosal nerve to reach the lacrimal gland. This
        results in tearing when the patient eats (38).
      explanation: >-
        The review describes gustatory tearing as an autonomic sequela of misdirected reinnervation.
      quote_role: REVIEW_SYNTHESIS
  locations:
  - preferred_term: facial nerve
    term:
      id: UBERON:0001647
      label: facial nerve
- name: Ocular surface exposure
  description: >-
    Impaired blinking and eyelid closure expose the cornea; inadequate lubrication can result in epithelial
    injury, exposure keratitis and corneal ulceration. This is a secondary complication of facial dysfunction,
    not a primary cause of the neuropathy.
  biological_scale: TISSUE
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Failure to protect the cornea among patients who are unable to blink adequately may result in corneal
      ulceration and permanent visual impairment.
    explanation: >-
      The guideline directly links inadequate protection in impaired blinking with corneal complications.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Corneal ulceration
    description: >-
      Unprotected exposure can damage the corneal epithelium.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
      reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Failure to protect the cornea among patients who are unable to blink adequately may result in corneal
        ulceration and permanent visual impairment.
      explanation: >-
        The guideline directly links inadequate protection in impaired blinking with corneal complications.
      quote_role: REVIEW_SYNTHESIS
phenotypes:
- name: Facial weakness
  category: Neurological
  frequency: OBLIGATE
  description: >-
    Acute unilateral lower motor neuron weakness of the muscles of facial
    expression is the defining phenotype of Bell's palsy.
  phenotype_term:
    preferred_term: acute unilateral peripheral facial weakness
    term:
      id: HP:0030319
      label: Weakness of facial musculature
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bell's palsy, also known as \"acute facial palsy of unknown cause\", is a common cranial neuropathy leading to facial muscle paresis or complete paralysis characteristically on one side, occurring suddenly and may progress over 48 hours."
    explanation: This directly supports acute unilateral peripheral facial weakness as the core phenotype of Bell's palsy.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Lagophthalmos
  category: Ophthalmologic
  description: >-
    Incomplete eyelid closure can accompany acute peripheral facial weakness and increases ocular surface exposure
    risk.
  phenotype_term:
    preferred_term: lagophthalmos
    term:
      id: HP:0030001
      label: Lagophthalmos
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Symptoms of Bell's palsy include the inability to blink or close the eye, ruck up the lips or raise the
      mouth corner
    explanation: >-
      The review describes motor manifestations of peripheral facial nerve dysfunction.
    quote_role: REVIEW_SYNTHESIS
  sequelae:
  - target: Ocular surface exposure
    description: >-
      Incomplete blinking and eyelid closure expose the corneal surface.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
      reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Failure to protect the cornea among patients who are unable to blink adequately may result in corneal
        ulceration and permanent visual impairment.
      explanation: >-
        The guideline directly links inadequate protection in impaired blinking with corneal complications.
      quote_role: REVIEW_SYNTHESIS
- name: Abnormal taste sensation
  category: Neurological
  description: >-
    Bell's palsy can impair taste sensation over the anterior tongue because
    facial nerve dysfunction affects the chorda tympani pathway.
  phenotype_term:
    preferred_term: altered taste sensation
    term:
      id: HP:0000223
      label: Abnormality of taste sensation
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
      in taste, and dry eyes caused by parasympathetic affliction.
    explanation: >-
      Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
    quote_role: REVIEW_SYNTHESIS
- name: Hyperacusis
  category: Auditory
  description: >-
    Heightened sound sensitivity can occur when facial nerve dysfunction
    impairs stapedius muscle function.
  phenotype_term:
    preferred_term: hyperacusis
    term:
      id: HP:0010780
      label: Hyperacusis
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
      in taste, and dry eyes caused by parasympathetic affliction.
    explanation: >-
      Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
    quote_role: REVIEW_SYNTHESIS
- name: Facial synkinesis
  category: Neurological
  description: >-
    Some patients develop persistent involuntary linked facial movements as a
    sequela of incomplete recovery and aberrant facial motor reinnervation.
  phenotype_term:
    preferred_term: facial synkinesis
    term:
      id: HP:0034979
      label: Facial synkinesis
  evidence:
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The synkinesis is a result of misguided nerve regeneration following axonal damage.
    explanation: >-
      This supports aberrant regeneration as the principal explanatory process for synkinesis.
    quote_role: REVIEW_SYNTHESIS
- name: Dry eyes
  description: >-
    Reduced tear secretion and exposure from incomplete blinking can cause ocular dryness.
  phenotype_term:
    preferred_term: Keratoconjunctivitis sicca
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  evidence:
  - reference: PMID:36397921
    reference_title: "Bell's Palsy: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Other symptoms include hyperacusis caused by nerve fiber breakdown in the stapedius muscle, alterations
      in taste, and dry eyes caused by parasympathetic affliction.
    explanation: >-
      Review-level support for associated facial nerve functions; no phenotype frequency is estimated.
    quote_role: REVIEW_SYNTHESIS
- name: Corneal ulceration
  category: Ophthalmologic
  description: >-
    A potentially serious secondary complication when impaired blinking or closure leaves the ocular surface
    inadequately protected; it is not present in every patient.
  phenotype_term:
    preferred_term: Corneal ulceration
    term:
      id: HP:0012804
      label: Corneal ulceration
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Failure to protect the cornea among patients who are unable to blink adequately may result in corneal
      ulceration and permanent visual impairment.
    explanation: >-
      The guideline directly links inadequate protection in impaired blinking with corneal complications.
    quote_role: REVIEW_SYNTHESIS
- name: Ear pain
  description: >-
    Mild ipsilateral pain around or behind the ear can accompany the acute episode. Severe pain, vesicles or
    abnormal otoscopy favor an alternative cause.
  phenotype_term:
    preferred_term: Ear pain
    term:
      id: HP:0030766
      label: Ear pain
  evidence:
  - reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
    reference_title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Facial pain: usually mild pain in the face or behind the ear (common in Bell palsy)
    explanation: >-
      The guideline describes mild facial or postauricular discomfort; it does not establish a numeric frequency.
    quote_role: REVIEW_SYNTHESIS
- name: Gustatory lacrimation
  description: >-
    Meal-triggered tearing, also called crocodile tears, can occur after facial nerve regeneration. No population
    frequency is inferred from the review wording.
  phenotype_term:
    preferred_term: Gustatory lacrimation
    term:
      id: HP:0100274
      label: Gustatory lacrimation
  evidence:
  - *id001
genetic:
- name: Common susceptibility locus at 6p21.1
  association: SUSCEPTIBILITY
  notes: >-
    The common intergenic rs9357446-A allele at 6p21.1 was associated with Bell's palsy in 4,714 cases and
    1,011,520 controls from Iceland, the UK, Denmark and Finland (OR 1.23). The risk allele was common, not
    a high-penetrance Mendelian cause. Linked variants were noncoding; no correlated coding or structural variant
    was identified. Blood/adipose and 18 other expression datasets did not nominate an expression target, and
    4,792 plasma-protein measurements did not establish a protein effect. Nearby CDC5L and SLC35B2 remain speculative
    candidates, not proven causal genes. Noncoding location alone does not establish enhancer disruption or
    a regulatory target.
  evidence:
  - reference: PMID:33602968
    reference_title: "A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report findings from a meta-analysis of genome-wide association studies uncovering the first unequivocal association with Bell's palsy (rs9357446-A; P = 6.79 × 10-23, OR = 1.23; Ncases = 4714, Ncontrols = 1,011,520)."
    explanation: This supports a reproducible common-genetic susceptibility signal for Bell's palsy.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:33602968
    reference_title: A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The variant is not correlated (r2 < 0.2) with any known coding or structural variants.
    explanation: >-
      This restricts the associated locus to an unresolved noncoding signal.
    quote_role: PRIMARY_RESULT
  - reference: PMID:33602968
    reference_title: A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      We examined cis-eQTL in blood and adipose tissue in Iceland and did not find an association between rs9357446
      and expression of nearby genes (Supplementary Note).
    explanation: >-
      Negative expression analyses do not support naming a regulatory target gene.
    quote_role: PRIMARY_RESULT
diagnosis:
- name: Clinical history and neurologic physical examination
  description: >-
    Diagnosis requires acute peripheral facial weakness and a focused history, full neurologic examination,
    ear/skin examination and assessment of eye closure. Forehead involvement supports a peripheral pattern
    but is not sufficient to exclude every stroke. Typical new-onset Bell's palsy does not require routine
    laboratory tests or imaging; targeted investigation follows exposure history, systemic signs, progression
    or other atypical findings.
  diagnosis_term:
    preferred_term: physical examination
    term:
      id: NCIT:C20989
      label: Physical Examination
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
    explanation: This directly supports diagnosis by focused clinical evaluation and exclusion of key mimics.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should not obtain routine laboratory testing in patients with new-onset Bell's palsy
    explanation: >-
      The recommendation applies to a typical clinical presentation, not to a patient with features suggesting
      another cause.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should not routinely perform diagnostic imaging for patients with new-onset Bell's palsy
    explanation: >-
      Routine imaging is unnecessary in otherwise typical new-onset disease.
    quote_role: REVIEW_SYNTHESIS
- name: Selective electromyography
  description: >-
    AAO-HNSF guidance advises against electrodiagnostic testing for typical incomplete facial paresis and permits
    it in complete paralysis. Needle EMG can assess axonal degeneration, reinnervation and established synkinesis;
    denervation changes may not appear until 10-14 days, with testing most informative from about two to three
    weeks. The 2020 international electrodiagnostic guideline notes that some national guidelines recommend
    broader testing.
  diagnosis_term:
    preferred_term: electromyography procedure
    term:
      id: NCIT:C38056
      label: Electromyography
  evidence:
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should not perform electrodiagnostic testing in Bell's palsy patients with incomplete facial
      paralysis
    explanation: >-
      This prevents routine EMG recommendations based only on a trial's testing protocol.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:32270328
    reference_title: 'Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Signs of muscle degeneration cannot be seen by EMG before 10–14 days.
    explanation: >-
      An early normal EMG does not exclude evolving axonal injury.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:32270328
    reference_title: 'Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      In contrast, the German and the Spanish guidelines recommend electrodiagnostics for all patients with
      Bell’s palsy
    explanation: >-
      Specialty guidance differs on the breadth of testing; the AAO-HNSF recommendation is identified by source.
    quote_role: REVIEW_SYNTHESIS
- name: Electroneuronography in complete paralysis
  description: >-
    Electroneuronography compares evoked facial-muscle responses between affected and unaffected sides to estimate
    degeneration. In complete palsy it can inform prognosis, interpreted together with EMG and clinical severity.
    Responses may remain normal during the first 72 hours; the useful acute window is approximately 72 hours
    to 21 days. Severe degeneration is a prognostic finding, not proof that decompression surgery will improve
    outcome.
  diagnosis_term:
    preferred_term: nerve conduction study
    term:
      id: NCIT:C88502
      label: Nerve Conduction Velocity Test
  evidence:
  - reference: PMID:32270328
    reference_title: 'Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      ENoG can show completely normal results during this 72-h window.
    explanation: >-
      Wallerian degeneration has not necessarily reached the distal stimulation segment immediately after an
      intratemporal lesion.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:32270328
    reference_title: 'Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      ENoG is most valuable within the time window of 72 h to 21 days after onset of the lesion.
    explanation: >-
      The guideline provides the timing needed for interpreting this prognostic test.
    quote_role: REVIEW_SYNTHESIS
- name: Facial function and synkinesis grading
  description: >-
    House-Brackmann and Sunnybrook scores document baseline severity and recovery. For persistent synkinesis,
    Sunnybrook or eFACE assessment and the Synkinesis Assessment Questionnaire capture clinician and patient
    perspectives; a global facial score alone can miss the pattern or impact of involuntary movements.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Commonly used facial grading instruments (e,g., House–Brackmann and Sunnybrook scales) quantify the severity
      of facial weakness.
    explanation: >-
      Standardized grading documents severity rather than replacing etiologic diagnosis.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The Synkinesis Assessment Questionnaire (SAQ) is a specific PROM for the evaluation of synkinesis
    explanation: >-
      A dedicated patient-reported measure complements facial movement examination.
    quote_role: REVIEW_SYNTHESIS
- name: Reassessment and targeted imaging for atypical or persistent palsy
  description: >-
    Reassess or refer for new or worsening neurologic findings, ocular symptoms at any time, or incomplete
    facial recovery at three months. Persistent progressive weakness requires evaluation along the facial nerve
    course for structural causes, using specialist-directed MRI or high-resolution CT as appropriate. This
    is distinct from routine imaging of typical acute Bell's palsy.
  evidence:
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should reassess or refer to a facial nerve specialist those Bell's palsy patients with (1)
      new or worsening neurologic findings at any point, (2) ocular symptoms developing at any point, or (3)
      incomplete facial recovery 3 months after initial symptom onset.
    explanation: >-
      The guideline defines concrete reassessment triggers.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      We recommend imaging to rule out neoplasms or alternative diagnoses for patients with no improvement
      or progressive weakness.
    explanation: >-
      Persistent or progressive dysfunction changes the investigation threshold.
    quote_role: REVIEW_SYNTHESIS
treatments:
- name: Early oral corticosteroids in adults
  description: >-
    Oral corticosteroids improve recovery in adults when started within 72 hours; the AAO-HNSF recommendation
    applies to patients aged 16 years and older. Two large placebo-controlled factorial trials support prednisolone.
    In the 2007 study, complete recovery at three months was 83.0% with prednisolone versus 63.6% without it,
    and at nine months 94.4% versus 81.6%. These are factorial comparisons, not a comparison of combination
    therapy with double placebo. Contraindications and individual risks still require clinical assessment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
  evidence:
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should prescribe oral steroids within 72 hours of symptom onset for Bell's palsy patients
      16 years and older
    explanation: >-
      This provides the treatment window and age scope.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:17942873
    reference_title: Early treatment with prednisolone or acyclovir in Bell's palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      In patients with Bell's palsy, early treatment with prednisolone significantly improves the chances of
      complete recovery at 3 and 9 months.
    explanation: >-
      The 551-participant randomized factorial trial supports adult steroid benefit.
    quote_role: PRIMARY_RESULT
  - reference: PMID:18849193
    reference_title: "Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Prednisolone shortened the time to complete recovery in patients with Bell's palsy, whereas valaciclovir
      did not affect facial recovery.
    explanation: >-
      An independent multicenter trial randomized 839 adults and analyzed 829, corroborating prednisolone benefit.
    quote_role: PRIMARY_RESULT
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Facial nerve edema within the facial canal
    description: >-
      Anti-inflammatory therapy is intended to reduce swelling; efficacy trials establish recovery benefit,
      not direct measurement of local nerve edema.
    evidence:
    - reference: PMID:36397921
      reference_title: "Bell's Palsy: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        Prednisone and other oral corticosteroids reduce nerve swelling and may speed up the recovery of facial
        actions and expressions.
      explanation: >-
        Review-level mechanistic rationale for corticosteroid treatment.
      quote_role: REVIEW_SYNTHESIS
- name: Adjunctive antiviral therapy
  description: >-
    Acyclovir or valacyclovir may be offered with corticosteroids within 72 hours, with discussion of uncertain
    additional recovery benefit; antiviral monotherapy is not recommended. The 2019 Cochrane analysis restricted
    to trials at lower risk of bias found no clear improvement in incomplete recovery (RR 0.81, 95% CI 0.38-1.74),
    including an imprecise severe-palsy subgroup. Combination treatment probably reduces the composite late
    outcome of synkinesis or crocodile tears. A small 50-patient trial reported better recovery with add-on
    acyclovir, but this does not override the larger trials or pooled uncertainty.
  treatment_term:
    preferred_term: antiviral therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: acyclovir
      term:
        id: CHEBI:2453
        label: acyclovir
    - preferred_term: valacyclovir
      term:
        id: CHEBI:35854
        label: valacyclovir
  evidence:
  - reference: PMID:31486071
    reference_title: Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete
      recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in
      people with severe Bell's palsy, but the results were very imprecise.
    explanation: >-
      The synthesis separates uncertain facial recovery benefit from sequelae reduction.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:31486071
    reference_title: Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy
      compared with corticosteroids alone.
    explanation: >-
      The pooled composite of motor synkinesis or crocodile tears favored combination therapy (RR 0.56, 95%
      CI 0.36-0.87, two trials with 469 participants); it is not a separate estimate for each component.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:27689547
    reference_title: "Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      At the end of the 3rd month, 17 patients (68%) had good recovery and 8 patients (32%) had poor recovery
      in the steroid group compared with 23 patients (92%) and 2 (8%) respectively in the steroid and antiviral
      group
    explanation: >-
      The small trial reports a positive comparison that must be considered alongside larger studies and risk-of-bias-sensitive
      synthesis.
    quote_role: PRIMARY_RESULT
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should not prescribe oral antiviral therapy alone for patients with new-onset Bell's palsy
    explanation: >-
      Antivirals alone are not a recommended substitute for corticosteroids.
    quote_role: REVIEW_SYNTHESIS
  therapeutic_modality: SMALL_MOLECULE
- name: Facial physical therapy
  description: >-
    Specialist facial neuromuscular retraining, with feedback where available, is first-line management for
    established synkinesis and can help persistent weakness. The aim in synkinesis is selective control of
    intended movements and relaxation of unintended contractions. Evidence and goals differ from acute-phase
    exercises; studies vary in timing, method and quality.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy and Botox injections can help patients with persistent symptoms."
    explanation: This supports physical therapy as a symptomatic treatment for persistent Bell's palsy deficits.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Facial training is the basis of synkinesis therapy.
    explanation: >-
      International consensus places tailored training first in established synkinesis.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:38517799
    reference_title: 'Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Outcomes of studies with physical therapy varied, regarding recovery rate and time to recovery, although
      most studies showed better outcomes for physical therapy, compared to usual care.
    explanation: >-
      This sentence is from the Bell's palsy subgroup of a multi-disease review, not an extrapolation from
      FSHD.
    quote_role: REVIEW_SYNTHESIS
  target_phenotypes:
  - preferred_term: Facial synkinesis
    term:
      id: HP:0034979
      label: Facial synkinesis
- name: Botulinum toxin type A therapy
  description: >-
    Specialist botulinum toxin type A injections can reduce troublesome synkinetic contractions after incomplete
    recovery, often alongside retraining. This is symptomatic, off-label management of established synkinesis;
    unintended weakness can occur through excessive dose or diffusion to adjacent muscles. It does not restore
    an injured facial nerve.
  treatment_term:
    preferred_term: botulinum toxin type A therapy
    term:
      id: NCIT:C157775
      label: Botulinum Toxin Therapy
    therapeutic_agent:
    - preferred_term: Botulinum toxin type A
      term:
        id: CHEBI:3160
        label: Botulinum toxin type A
  target_phenotypes:
  - preferred_term: facial synkinesis
    term:
      id: HP:0034979
      label: Facial synkinesis
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy and Botox injections can help patients with persistent symptoms."
    explanation: This supports botulinum toxin treatment for persistent Bell's palsy sequelae such as synkinesis and asymmetry.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:36438936
    reference_title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Botulinum toxin injections are an established and effective but off-label use therapy for patients with
      facial synkinesis worldwide
    explanation: >-
      Consensus supports symptomatic treatment of synkinesis, not treatment of the acute neuropathy.
    quote_role: REVIEW_SYNTHESIS
  therapeutic_modality: OTHER
- name: Eye lubrication and eyelid protection
  description: >-
    Protect the cornea whenever eye closure or blinking is incomplete. Lubricating drops during the day and
    lubricating ointment with assisted eyelid closure at night reduce exposure. Eye pain, redness or visual
    symptoms require reassessment. Eye care remains necessary regardless of whether corticosteroids or antivirals
    are used.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: corneal protection with ocular lubrication and assisted eyelid closure
  target_phenotypes:
  - preferred_term: Lagophthalmos
    term:
      id: HP:0030001
      label: Lagophthalmos
  evidence:
  - reference: PMID:24189771
    reference_title: "Clinical practice guideline: Bell's palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      clinicians should implement eye protection for Bell's palsy patients with impaired eye closure.
    explanation: >-
      Eye protection is a strong care recommendation.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Patients with incomplete eye closure should be given eye protection, with lubricating drops and ointments,
      to prevent corneal damage.
    explanation: >-
      This supports concrete protective measures.
    quote_role: REVIEW_SYNTHESIS
  notes: >-
    A precise unbound descriptor represents this combined supportive-care intervention; it is not equivalent
    to an unrelated ophthalmic operation.
- name: 'Prednisolone in children: uncertain benefit'
  description: >-
    Adult corticosteroid efficacy should not be assumed in younger children. BellPIC randomized 187 children
    aged six months to under 18 years within 72 hours, rather than the planned 540. Ten days of prednisolone
    did not improve complete recovery at one month (49% versus 57% with placebo); the study was underpowered
    and cannot exclude important benefit or harm. Most children recovered by six months. Pediatric guidance
    therefore describes insufficient evidence for routine early prednisolone.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:36008143
    reference_title: 'Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      This study, although underpowered, does not provide evidence that early treatment with prednisolone improves
      complete recovery.
    explanation: >-
      Absence of demonstrated benefit in an underpowered trial is not proof of equivalence.
    quote_role: PRIMARY_RESULT
  - reference: url:https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
    reference_title: https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The results of these secondary outcomes suggest caution in interpreting the primary outcome result in
      isolation as evidence that prednisolone provides no clinical benefit in the management of Bell’s palsy
      in children.
    explanation: >-
      The full manuscript explicitly cautions against an absolute no-benefit conclusion.
    quote_role: PRIMARY_RESULT
  - reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
    reference_title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      There is not enough evidence that early treatment with prednisolone improves complete recovery in children
    explanation: >-
      The pediatric guideline distinguishes child evidence from adult treatment recommendations.
    quote_role: REVIEW_SYNTHESIS
- name: 'Facial nerve decompression: uncertain benefit'
  description: >-
    Decompression has been studied for severe paralysis with substantial electrophysiologic degeneration but
    is not routine care. Canadian guidance recommends against routine decompression because evidence is weak
    and surgery can cause hearing loss, further nerve injury or cerebrospinal fluid leak. A retrospective comparison
    of 15 operated and 30 conservatively treated severe cases found no significant added benefit from transmastoid
    surgery at 21-70 days. It does not establish whether other surgical timing or approaches benefit selected
    patients.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical decompression of the facial nerve
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      We suggest against the routine use of surgical decompression.
    explanation: >-
      The guideline recommendation reflects uncertain benefit and operative risks.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:35160337
    reference_title: Comparison of Medical and Surgical Treatment in Severe Bell's Palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Although we found that surgical decompression (performed 21–70 days after symptom onset) in severe Bell’s
      palsy improved functional outcomes, the functional improvement was not statistically different from that
      of the control group at the 6-month follow-up.
    explanation: >-
      The controlled observational comparison does not show added benefit; spontaneous recovery and treatment
      selection constrain inference.
    quote_role: PRIMARY_RESULT
  notes: >-
    The paper reports inconsistent recovery percentages and counts between its abstract and Table 2; the consistent
    finding is the nonsignificant comparison. The general surgical-procedure binding is narrowed by the facial
    nerve decompression descriptor.
- name: 'Intratympanic dexamethasone: investigational'
  description: >-
    Local dexamethasone injection has been studied as an adjunct or alternative when oral steroids cannot be
    given. NCT03508440 is a completed phase II/III study with only ten participants: one received oral steroids
    alone, nine received oral steroids plus injection, and none received injection alone. This extreme imbalance
    does not establish comparative efficacy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dexamethasone
      term:
        id: CHEBI:41879
        label: dexamethasone
  evidence:
  - reference: clinicaltrials:NCT03508440
    reference_title: Intratympanic Steroid Injection for Treatment of Idiopathic Facial Nerve Paralysis
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      There are indications that the use of intratympanic injections, in addition to the oral steroids, will
      speed up the recovery rate of the facial nerve paralysis, as well as improve the complete recovery of
      the facial nerve paralysis.
    explanation: >-
      This is the registered rationale, not an efficacy result.
    quote_role: BACKGROUND
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT03508440
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT03508440
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Injection only was for participants who could not, for medical reasons, receive the SOC treatment. We
      did not have any patients that met that criteria ... "type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"}]
    explanation: >-
      The participant-flow groups are oral standard care, standard care plus injection and injection alone,
      respectively. The extreme imbalance precludes a reliable comparative treatment estimate.
    quote_role: PRIMARY_RESULT
- name: 'Laser acupuncture and photobiomodulation: investigational'
  description: >-
    A single-center randomized trial in 84 adults with persistent palsy reported better facial grading and
    electrophysiologic outcomes with combined laser acupuncture/photobiomodulation than with lower-intensity
    laser exposure. Treating physicians were unblinded and the comparator delivered laser energy. Inconsistent
    duration and follow-up reporting and lack of independent replication limit interpretation; this is not
    established routine treatment or evidence for a specific molecular mechanism. The trial excluded complete
    paralysis and marked electrophysiologic degeneration, limiting applicability to the most severe cases.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: Photobiomodulation Therapy
    term:
      id: NCIT:C21063
      label: Photobiomodulation Therapy
  evidence:
  - reference: PMID:38216803
    reference_title: "Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The findings of this randomized controlled trial, single-center study suggest that laser acupuncture
      and photobiomodulation therapy relieve symptoms for patients with Bell’s palsy over 8 weeks.
    explanation: >-
      The study reports clinical improvement in persistent palsy, with design and reporting limitations.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38216803
    reference_title: "Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The study patients and data analysts were blinded to intervention assignment, but the physicians were
      not blinded.
    explanation: >-
      Unblinded treating clinicians constrain confidence in a single-center study.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38216803
    reference_title: "Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The control group received the same Multiwave Locked System device, same points in affected face and
      acupoints.
    explanation: >-
      The comparator was a lower-energy active device setting rather than a laser-off sham.
    quote_role: PRIMARY_RESULT
  notes: >-
    The methods state 72 sessions at three per week and outcomes at day 180, whereas results repeatedly say
    12 weeks. The methods exclude disease duration over one year but Table 2 lists mean durations of about
    14 months. These unresolved inconsistencies preclude adopting a precise treatment schedule from this report.
differential_diagnoses:
- name: Stroke
  disease_term:
    preferred_term: stroke disorder
    term:
      id: MONDO:0005098
      label: stroke disorder
  description: >-
    Acute facial weakness from stroke can mimic Bell's palsy, but Bell's
    palsy produces a peripheral facial weakness pattern and is diagnosed only
    after alternative causes are excluded.
  distinguishing_features:
  - Typical Bell's palsy affects the upper and lower ipsilateral face. Forehead sparing suggests a supranuclear lesion, but forehead involvement alone cannot exclude a brainstem lesion.
  - Additional limb weakness, ataxia, diplopia or other neurologic deficits require urgent evaluation for an alternative diagnosis.
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
    explanation: This directly supports stroke as an important alternative diagnosis that must be excluded.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
    reference_title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Other neurological features such as severe headache, blurred vision, double vision, weakness/numbness
      in arms or extremities, ataxia
    explanation: >-
      Associated neurologic signs are red flags rather than part of uncomplicated Bell's palsy.
    quote_role: REVIEW_SYNTHESIS
- name: Lyme disease
  disease_term:
    preferred_term: Lyme disease
    term:
      id: MONDO:0019632
      label: Lyme disease
  description: >-
    Lyme neuroborreliosis can present with acute facial palsy and should be
    considered in the appropriate epidemiologic setting.
  distinguishing_features:
  - Lyme disease is suggested by tick exposure, compatible geography, systemic symptoms, or other evidence of Borrelia infection.
  - Bell's palsy remains idiopathic after focused evaluation and exclusion of alternative infectious causes.
  evidence:
  - reference: PMID:39939082
    reference_title: "Bell's Palsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a thorough history and physical examination, with careful attention to exclude other causes of facial weakness, such as stroke or Lyme disease."
    explanation: This directly supports Lyme disease as a clinically important differential diagnosis for Bell's palsy.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Melkersson-Rosenthal syndrome
  disease_term:
    preferred_term: Melkersson-Rosenthal syndrome
    term:
      id: MONDO:0007969
      label: Melkersson-Rosenthal syndrome
  description: >-
    Melkersson-Rosenthal syndrome can include facial paralysis, but it is
    distinguished by recurrent disease together with lip or facial edema and a
    fissured tongue.
  distinguishing_features:
  - Melkersson-Rosenthal syndrome includes additional recurrent orofacial edema and fissured tongue rather than isolated acute idiopathic facial weakness.
  - Bell's palsy is typically an isolated acute peripheral facial palsy without the classic granulomatous syndrome features.
  evidence:
  - reference: PMID:40255708
    reference_title: "Cheilitis Granulomatosa: A Case Report of a Sarcoid Mimic."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CG can occur as an isolated condition or as part of Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue."
    explanation: >-
      The case-report background describes the Melkersson-Rosenthal syndrome triad; the reported patient did
      not establish a Bell's palsy mechanism.
    directness: DIRECT
    quote_role: BACKGROUND
- name: Ramsay Hunt syndrome and other otologic causes
  description: >-
    Varicella-zoster-associated peripheral facial palsy, otitis media, mastoiditis and other ear disease require
    a different etiologic diagnosis. Ear or oral vesicles, severe otalgia, hearing or vestibular symptoms,
    or abnormal otoscopy should prompt targeted assessment.
  distinguishing_features:
  - Ramsay Hunt syndrome can produce ear-canal or facial vesicles with peripheral facial palsy.
  - Severe pain or local ear findings favor a specific otologic or infectious cause over uncomplicated idiopathic palsy.
  evidence:
  - reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
    reference_title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Skin lesions or vesicles on the face or in the ear canal (Ramsay Hunt Syndrome)
    explanation: >-
      The pediatric guideline identifies vesicles as a discriminator.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
    reference_title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Severe pain (may indicate mastoiditis, VZV)
    explanation: >-
      Severe otalgia is a red flag for an alternative otologic or infectious cause.
    quote_role: REVIEW_SYNTHESIS
- name: Structural facial nerve lesions
  description: >-
    Facial nerve schwannoma, skull-base neoplasm or parotid pathology may cause progressive or nonrecovering
    facial weakness. Persistent progression requires reassessment and imaging rather than indefinite attribution
    to Bell's palsy.
  distinguishing_features:
  - Progressive weakness or failure to improve prompts investigation of the facial nerve course.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
    reference_title: 'Management of Bell palsy: clinical practice guideline - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Referral to a specialist may avoid missed diagnoses of malignant skull-base neoplasms
    explanation: >-
      The guideline highlights structural mimics in patients who fail to improve.
    quote_role: REVIEW_SYNTHESIS
clinical_trials:
- name: NCT03508440
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Completed phase II/III intratympanic dexamethasone study in acute moderate-to-severe palsy. The posted
    results include ten participants: one on oral steroids alone and nine on oral steroids plus injection;
    no participant received injection alone. Reported mean recovery times cannot establish comparative efficacy
    with a single control participant.
  target_phenotypes:
  - preferred_term: facial weakness
    term:
      id: HP:0030319
      label: Weakness of facial musculature
  evidence:
  - reference: clinicaltrials:NCT03508440
    reference_title: "Intratympanic Steroid Injection for Treatment of Idiopathic Facial Nerve Paralysis"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There are indications that the use of intratympanic injections, in addition to the oral steroids, will speed up the recovery rate of the facial nerve paralysis, as well as improve the complete recovery of the facial nerve paralysis."
    explanation: This ClinicalTrials.gov record supports a Bell's palsy trial evaluating adjunct intratympanic steroid therapy to improve recovery.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT03508440
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT03508440
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Injection only was for participants who could not, for medical reasons, receive the SOC treatment. We
      did not have any patients that met that criteria ... "type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"}]
    explanation: >-
      The participant-flow groups are oral standard care, standard care plus injection and injection alone,
      respectively. The extreme imbalance precludes a reliable comparative treatment estimate.
    quote_role: PRIMARY_RESULT
  notes: >-
    ClinicalTrials.gov was checked on 1 October 2026. The schema stores one phase, so PHASE_III represents
    the higher component of the registered PHASE2/PHASE3 designation. The API cache contains posted results
    absent from the summary cache.
- name: NCT05846217
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Completed randomized single-center trial of combined laser acupuncture/photobiomodulation for persistent
    palsy, with 84 randomized adults and lower-intensity laser settings as comparator. The linked publication
    reports better facial scores but contains inconsistent timing and disease-duration statements; it does
    not establish a standard treatment regimen.
  target_phenotypes:
  - preferred_term: facial weakness
    term:
      id: HP:0030319
      label: Weakness of facial musculature
  evidence:
  - reference: clinicaltrials:NCT05846217
    reference_title: "Bell's Palsy With a Duration of Greater Than 8 Weeks Treated With Multiwave Locked System Intervention: A Randomized Controlled Trial"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OBJECTIVE: To determine whether photobiomodulation therapy by class IV Multiwave Locked System laser treatment could relieve symptoms in patients with Bell's palsy with a duration of greater than 8 weeks."
    explanation: This ClinicalTrials.gov record supports an interventional trial for persistent Bell's palsy symptoms using photobiomodulation therapy.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:38216803
    reference_title: "Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      A total of 84 participants were included (42 control group, 42 laser acupuncture group).
    explanation: >-
      The registered study has published results, with reporting limitations described in the treatment entry.
    quote_role: PRIMARY_RESULT
- name: NCT02328079
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Fifty-patient randomized study of steroid alone versus steroid plus antiviral in moderately severe to complete
    acute palsy, published in 2016. The paper reports greater recovery with combination therapy at three months.
    ClinicalTrials.gov lists unmasked allocation whereas the publication describes double blinding; this unresolved
    discrepancy and small sample size limit certainty.
  evidence:
  - reference: PMID:27689547
    reference_title: "Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Fifty eligible patients out of a total of 65 with acute onset Bell's palsy were randomized to receive
      the two treatments.
    explanation: >-
      This is the small positive trial; it is not a substitute for the larger placebo-controlled evidence.
    quote_role: PRIMARY_RESULT
  - reference: PMID:27689547
    reference_title: "Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      This study was registered with ClinicalTrials.gov, number NCT02328079.
    explanation: >-
      The publication explicitly links the clinical result to the registration.
    quote_role: PRIMARY_RESULT
  notes: >-
    ClinicalTrials.gov checked 1 October 2026: completed, actual enrollment 50, phase not applicable; no registry
    results posted.
- name: NCT00510263
  phase: PHASE_IV
  status: COMPLETED
  description: >-
    Scandinavian factorial placebo-controlled study of prednisolone and valaciclovir in adults aged 18-75 years
    presenting within 72 hours. Of 839 randomized patients, 829 were analyzed. Prednisolone shortened time
    to complete recovery; valaciclovir did not. Follow-up lasted twelve months.
  evidence:
  - reference: clinicaltrials:NCT00510263
    reference_title: A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The main objective of this study is to study the effects of prednisolone and valaciclovir, with equal
      importance, compared to placebo for the treatment of Bell´s palsy.
    explanation: >-
      The registry establishes the factorial study question; efficacy is supported by the publication.
    quote_role: BACKGROUND
  - reference: PMID:18849193
    reference_title: "Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Prednisolone shortened the time to complete recovery in patients with Bell's palsy, whereas valaciclovir
      did not affect facial recovery.
    explanation: >-
      The trial's published outcome supports steroids and reports no valaciclovir recovery effect.
    quote_role: PRIMARY_RESULT
  notes: >-
    ClinicalTrials.gov checked 1 October 2026: phase IV, completed.
- name: ACTRN12615000563561
  phase: PHASE_III
  description: >-
    BellPIC compared ten days of prednisolone with placebo in children aged six months to under 18 years presenting
    within 72 hours. The published trial randomized 187 of the intended 540 children and did not show improved
    complete recovery at one month. The uncertainty around longer-term effects must be retained.
  evidence:
  - reference: ICTRP:ACTRN12615000563561
    reference_title: "Bell's Palsy in Children: A Multi-centre, double-blind, Randomised, Placebo-controlled Trial to Determine Whether Prednisolone Improves Recovery at 1 Month."
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Participants assigned to the intervention will receive 1mg/kg/day of prednisolone (dosing is based on
      weight categories) up to a maximum of 50mg/day for 10 days.
    explanation: >-
      The registry confirms the intervention and registration identity, not efficacy.
  - reference: PMID:36008143
    reference_title: 'Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      This study, although underpowered, does not provide evidence that early treatment with prednisolone improves
      complete recovery.
    explanation: >-
      The published randomized trial is the source for the outcome.
    quote_role: PRIMARY_RESULT
  notes: >-
    The generated ICTRP snapshot, refreshed 8 September 2025, still says Recruiting despite the published enrollment
    ending in 2020. Recruitment status is left unset rather than treating that discordant snapshot as current.
    The published result and target sample size are distinguished.
- name: ISRCTN71548196
  status: COMPLETED
  description: >-
    Scottish 2-by-2 factorial trial of prednisolone, acyclovir, both or double placebo within 72 hours. It
    randomized 551 patients and obtained final outcomes for 496. Prednisolone improved complete recovery at
    three and nine months; acyclovir added no demonstrated recovery benefit.
  evidence:
  - reference: ICTRP:ISRCTN71548196
    reference_title: "Bell's palsy: Early aciclovir and/or prednisolone in Scotland"
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Inclusion criteria: Adults (16 or older) diagnosed with Bell's Palsy and with no excluding conditions
      and who can be consented at participating centres in Scotland within 72 hours of onset.
    explanation: >-
      The registration defines the adult population and treatment window.
  - reference: PMID:17942873
    reference_title: Early treatment with prednisolone or acyclovir in Bell's palsy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      There is no evidence of a benefit of acyclovir given alone or an additional benefit of acyclovir in combination
      with prednisolone.
    explanation: >-
      The trial separates the prednisolone effect from the lack of demonstrated antiviral recovery benefit.
    quote_role: PRIMARY_RESULT
  notes: >-
    The ICTRP registration lists the original target of 720 participants and a completed status in its 2015
    snapshot; the publication reports 551 actually randomized. No phase is assigned because this registration
    does not state one.
references:
- reference: ICTRP:ACTRN12615000563561
  title: "Bell's Palsy in Children: A Multi-centre, double-blind, Randomised, Placebo-controlled Trial to Determine Whether Prednisolone Improves Recovery at 1 Month."
- reference: PMID:17942873
  title: Early treatment with prednisolone or acyclovir in Bell's palsy.
- reference: PMID:18849193
  title: "Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial."
- reference: PMID:24189771
  title: "Clinical practice guideline: Bell's palsy."
- reference: PMID:24934895
  title: 'Management of Bell palsy: clinical practice guideline.'
- reference: PMID:27689547
  title: "Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial."
- reference: PMID:31124964
  title: 'Increased risk of Bell palsy in patient with migraine: A longitudinal follow-up study.'
- reference: PMID:31486071
  title: Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
- reference: PMID:32270328
  title: 'Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.'
- reference: PMID:33602968
  title: A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
- reference: PMID:34640384
  title: Clinical Prognostic Factors Associated with Good Outcomes in Pediatric Bell's Palsy.
- reference: PMID:35160337
  title: Comparison of Medical and Surgical Treatment in Severe Bell's Palsy.
- reference: PMID:36008143
  title: 'Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.'
- reference: PMID:36397921
  title: "Bell's Palsy: A Review."
- reference: PMID:36438936
  title: 'Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.'
- reference: PMID:37752723
  title: 'Psychosocial functioning in patients with altered facial expression: a scoping review in five neurological diseases.'
- reference: PMID:38216803
  title: "Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial."
- reference: PMID:38517799
  title: 'Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases.'
- reference: PMID:39939082
  title: Bell's Palsy.
- reference: PMID:40255708
  title: 'Cheilitis Granulomatosa: A Case Report of a Sarcoid Mimic.'
- reference: PMID:40299566
  title: Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.
- reference: PMID:41099890
  title: 'A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.'
- reference: PMID:7503474
  title: 'Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle.'
- reference: clinicaltrials:NCT00510263
  title: A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy
- reference: clinicaltrials:NCT03508440
  title: Intratympanic Steroid Injection for Treatment of Idiopathic Facial Nerve Paralysis
- reference: clinicaltrials:NCT05846217
  title: "Bell's Palsy With a Duration of Greater Than 8 Weeks Treated With Multiwave Locked System Intervention: A Randomized Controlled Trial"
- reference: url:https://clinicaltrials.gov/api/v2/studies/NCT03508440
  title: https://clinicaltrials.gov/api/v2/studies/NCT03508440
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
  title: 'Management of Bell palsy: clinical practice guideline - PMC'
- reference: url:https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
  title: https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
- reference: url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
  title: 'Clinical Practice Guidelines : Facial weakness and Bell palsy'
- reference: ICTRP:ISRCTN71548196
  title: "Bell's palsy: Early aciclovir and/or prednisolone in Scotland"
notes: >-
  The CMAJ full-text guideline is PMID:24934895; the generated PMC URL supplies its full recommendations because
  the PMID cache contains metadata only. The James Cook University PDF is the author manuscript of BellPIC
  (PMID:36008143); final PubMed abstract estimates are used where numerical details differ. The common-risk
  GWAS DOI identifies a publication, not a separately accessioned dataset. No single causal gene has been established
  at the 6p21.1 locus. The ClinicalTrials.gov API URL is the structured registry and posted-results record
  for NCT03508440, the intratympanic dexamethasone study.
mechanistic_hypotheses:
- hypothesis_group_id: VIRAL_REACTIVATION
  hypothesis_label: Herpesvirus reactivation as a possible initiating event
  status: ALTERNATIVE
  description: >-
    HSV-1 reactivation is a plausible initiating hypothesis supported by viral-DNA detection in selected clinical
    samples. It is not a demonstrated universal cause, and trials of antiviral treatment do not provide consistent
    evidence for added complete-recovery benefit.
  evidence:
  - reference: PMID:7503474
    reference_title: 'Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not
      in patients with the Ramsay-Hunt syndrome or in other controls.
    explanation: >-
      This human molecular observation is evidence for a viral hypothesis, not proof that all Bell's palsy
      is infectious.
    quote_role: PRIMARY_RESULT
discussions:
- discussion_id: INFLAMMATORY_PROTEOMICS
  prompt: Which inflammatory protein associations contribute causally to idiopathic facial nerve injury?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  rationale: >-
    A 2025 Mendelian-randomization and protein-network study nominated JAK/STAT-related inflammatory candidates.
    It used relaxed instrument thresholds, nominal testing and computational network hubs without direct facial-nerve
    experiments. The table reports low shared-variant posterior probabilities for CCL19, VCAM1, IL27RA and
    OSM (approximately 0.007-0.022), despite stronger claims in the discussion. These findings do not establish
    a causal edge from JAK/STAT activation to facial nerve edema or a clinical role for JAK inhibitors.
  evidence:
  - reference: PMID:40299566
    reference_title: Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    directness: DIRECT
    snippet: >-
      Four proteins, VCAM-1 (PP.H4: 0.022), CCL19 (PP.H4: 0.007), OSM (PP.H4: 0.011), and IL27RA (PP.H4: 0.02)
    explanation: >-
      These reported low PP.H4 values support the discussion's conclusion that shared causal variants have
      not been established; SUPPORT refers to that limitation, not to the proposed inflammatory causality.
    quote_role: PRIMARY_RESULT
  - reference: PMID:40299566
    reference_title: Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    directness: DIRECT
    snippet: >-
      composed of six hub proteins: JAK2, IL27RA, OSM, CCL19, SELL, and VCAM-1.
    explanation: >-
      Protein-network analysis nominated these hubs; it did not measure pathway activation in an affected human
      facial nerve.
    quote_role: PRIMARY_RESULT
- discussion_id: SLIT2_REPAIR
  prompt: Does SLIT2-ROBO signaling modify repair in human idiopathic facial palsy?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  rationale: >-
    A 2025 study combined Bell's palsy genetic associations with single-cell profiling and SLIT2 immunofluorescence
    in rat facial motor nuclei after mechanical nerve crush. Nominal plasma-protein MR associations and altered
    expression generate a repair hypothesis. Its PPH3+PPH4 threshold combines distinct-variant and shared-variant
    hypotheses and therefore does not by itself prove colocalization. CellChat and pseudotime are computational
    inferences; no SLIT2 perturbation or therapeutic rescue was performed. The rat lesion and central nuclear
    response do not reproduce the unknown initiating cause of human Bell's palsy.
  evidence:
  - reference: PMID:41099890
    reference_title: 'A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.'
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    directness: DIRECT
    snippet: >-
      Due to the limited power of colocalization analysis, we focused on genes with a combined posterior probability
      (PPH3 + PPH4) ≥ 0.8
    explanation: >-
      A sum including PPH3 cannot establish that exposure and disease share a single causal variant.
    quote_role: PRIMARY_RESULT
  - reference: PMID:41099890
    reference_title: 'A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: >-
      Immunofluorescence experiments further confirmed that SLIT2 protein expression in facial-nerve nucleus
      samples from the facial-nerve injury group was significantly higher than that in the control group
    explanation: >-
      Increased expression after a mechanical rat nerve injury is not proof of a causal or therapeutic SLIT2
      effect in human idiopathic disease.
    quote_role: PRIMARY_RESULT
animal_models:
- name: Mechanical facial nerve crush in Sprague-Dawley rats
  species: Rattus norvegicus
  description: >-
    Adult male rats underwent unilateral facial nerve crush near the stylomastoid foramen (50 g for 90 seconds),
    with sham surgery as control. Facial motor nuclei were sampled at 30 days for single-cell analysis; SLIT2
    expression was also examined by tissue immunofluorescence. This is an injury-and-repair analogue, not an
    etiologic model of idiopathic Bell's palsy.
  publication: PMID:41099890
  evidence:
  - reference: PMID:41099890
    reference_title: 'A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: >-
      A custom-made stainless-steel peripheral nerve clamp was used to damage the main trunk of the facial
      nerve. The clamp was applied with a pressure of 50 g for 90 s
    explanation: >-
      The intervention is mechanical nerve injury, not viral reactivation or spontaneous Bell's palsy.
    quote_role: PRIMARY_RESULT
  notes: >-
    Cell-type expression, inferred ligand-receptor communication and pseudotime do not demonstrate temporal
    lineage transitions or functional rescue. The paper did not intervene on SLIT2 or ROBO, and the response
    was measured in the central facial nucleus rather than the peripheral lesion.
  modeled_mechanisms:
  - target: Facial nerve axonal injury
    relationship: PARTIALLY_RECAPITULATES
    description: >-
      Mechanical nerve crush produces a peripheral injury with a subsequent central facial-nucleus response.
    fidelity: LOW
    limitations: >-
      Unknown human initiating etiology, peripheral inflammatory anatomy and species-specific motor-nucleus
      biology are not reproduced. No targeted rescue of SLIT2 signaling was tested.
    evidence:
    - reference: PMID:41099890
      reference_title: 'A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: DIRECT
      snippet: >-
        A custom-made stainless-steel peripheral nerve clamp was used to damage the main trunk of the facial
        nerve. The clamp was applied with a pressure of 50 g for 90 s
      explanation: >-
        The intervention is mechanical nerve injury, not viral reactivation or spontaneous Bell's palsy.
      quote_role: PRIMARY_RESULT
📚

References & Deep Research

References

31
ICTRP:ACTRN12615000563561
Bell's Palsy in Children: A Multi-centre, double-blind, Randomised, Placebo-controlled Trial to Determine Whether Prednisolone Improves Recovery at 1 Month.
No top-level findings curated for this source.
PMID:17942873
Early treatment with prednisolone or acyclovir in Bell's palsy.
No top-level findings curated for this source.
PMID:18849193
Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial.
No top-level findings curated for this source.
PMID:24189771
Clinical practice guideline: Bell's palsy.
No top-level findings curated for this source.
PMID:24934895
Management of Bell palsy: clinical practice guideline.
No top-level findings curated for this source.
PMID:27689547
Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial.
No top-level findings curated for this source.
PMID:31124964
Increased risk of Bell palsy in patient with migraine: A longitudinal follow-up study.
No top-level findings curated for this source.
PMID:31486071
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
No top-level findings curated for this source.
PMID:32270328
Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline.
No top-level findings curated for this source.
PMID:33602968
A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy.
No top-level findings curated for this source.
PMID:34640384
Clinical Prognostic Factors Associated with Good Outcomes in Pediatric Bell's Palsy.
No top-level findings curated for this source.
PMID:35160337
Comparison of Medical and Surgical Treatment in Severe Bell's Palsy.
No top-level findings curated for this source.
PMID:36008143
Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
No top-level findings curated for this source.
PMID:36397921
Bell's Palsy: A Review.
No top-level findings curated for this source.
PMID:36438936
Pathogenesis, diagnosis and therapy of facial synkinesis: A systematic review and clinical practice recommendations by the international head and neck scientific group.
No top-level findings curated for this source.
PMID:37752723
Psychosocial functioning in patients with altered facial expression: a scoping review in five neurological diseases.
No top-level findings curated for this source.
PMID:38216803
Laser acupuncture and photobiomodulation therapy in Bell's palsy with a duration of greater than 8 weeks: a randomized controlled trial.
No top-level findings curated for this source.
PMID:38517799
Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases.
No top-level findings curated for this source.
PMID:39939082
Bell's Palsy.
No top-level findings curated for this source.
PMID:40255708
Cheilitis Granulomatosa: A Case Report of a Sarcoid Mimic.
No top-level findings curated for this source.
PMID:40299566
Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.
No top-level findings curated for this source.
PMID:41099890
A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.
No top-level findings curated for this source.
PMID:7503474
Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle.
No top-level findings curated for this source.
clinicaltrials:NCT00510263
A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy
No top-level findings curated for this source.
clinicaltrials:NCT03508440
Intratympanic Steroid Injection for Treatment of Idiopathic Facial Nerve Paralysis
No top-level findings curated for this source.
clinicaltrials:NCT05846217
Bell's Palsy With a Duration of Greater Than 8 Weeks Treated With Multiwave Locked System Intervention: A Randomized Controlled Trial
No top-level findings curated for this source.
url:https://clinicaltrials.gov/api/v2/studies/NCT03508440
https://clinicaltrials.gov/api/v2/studies/NCT03508440
No top-level findings curated for this source.
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC4150706/
Management of Bell palsy: clinical practice guideline - PMC
No top-level findings curated for this source.
url:https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
https://researchonline.jcu.edu.au/76973/2/JCU_76973.pdf
No top-level findings curated for this source.
url:https://www.rch.org.au/clinicalguide/guideline_index/Facial_weakness_and_Bells_palsy/
Clinical Practice Guidelines : Facial weakness and Bell palsy
No top-level findings curated for this source.
ICTRP:ISRCTN71548196
Bell's palsy: Early aciclovir and/or prednisolone in Scotland
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Asta ▸
Asta Literature Retrieval: Disease Pathophysiology Research Template Target Disease Disease Name: Bell's palsy MONDO ID: (if available) Category...
Asta Scientific Corpus Retrieval 20 citations 2026-03-18T11:34:18.824082

Asta Literature Retrieval: Disease Pathophysiology Research Template Target Disease Disease Name: Bell's palsy MONDO ID: (if available) Category...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] A meta-analysis uncovers the first sequence variant conferring risk of Bell’s palsy

  • Authors: A. Skuladóttir, G. Bjornsdottir, G. Thorleifsson, G. Walters, M. S. Nawaz et al.
  • Year: 2021
  • Venue: Scientific Reports
  • URL: https://www.semanticscholar.org/paper/3f3bee81a0bfc0d39c79f29d7c437b305c42a9fe
  • DOI: 10.1038/s41598-021-82736-w
  • PMID: 33602968
  • PMCID: 7893061
  • Citations: 13
  • Summary: Findings from a meta-analysis of genome-wide association studies uncovering the first unequivocal association with Bell’s palsy are reported, suggesting a common pathogenesis in part or a true pleiotropy.
  • Evidence snippets:
  • Snippet 1 (score: 0.605) > The precise pathophysiology of Bell's palsy is unknown and biologically targeted treatment is lacking. The aim of the study was to search for variations in the human genome affecting risk of Bell's palsy and thus use genetics to uncover biological underpinnings of this somewhat mysterious disease. Here, we report the first unequivocal association between Bell's palsy and a sequence variant, rs9357446-A (P = 6.79 × 10 -23 , OR = 1.23), in a metaanalysis of four study cohorts. While rs9357446-A confers risk of Bell's palsy, it also confers low risk of IDD as well as reduced lung function measured by decreased FVC 16 suggesting shared etiology of these diverse diseases that are all but certain to differ in the pathogenesis. The common variant at 6p21.1 is intergenic. Nearby genes are LOC105375075, CDC5L, MIR4642, SPATS1, AARS2, TCTE1, TMEM151B, and SLC35B2. Our transcript-and proteomics analyses did not pinpoint a Bell's palsy gene at this locus. Although uncorrelated with rs9357446 (r 2 < 0.2), several sequence variants in the closest gene, cell division cycle 5 like (CDC5L), have been found to associate with related phenotypes, including osteoarthritis 17 , bone density 18 , ossification of the spine 19 , and lung function measured by FVC and forced expiratory volume 16 . Another potential candidate at the locus, SLC35B2, is a key component of a protein sulfation pathway where it plays a part in modifying C-C Motif Chemokine Receptor 5 (CCR5), that is one of HIV's host proteins for entry into the cell 20 . Several other studies point to the importance of CCR5 in determining disease severity of other viral infections in animal models 21,22 . In addition, SLC35B2 is involved in proteoglycan synthesis. Cartilage is particularly rich in proteoglycans, and changes in the structure and composition

[2] Comparison of Medical and Surgical Treatment in Severe Bell’s Palsy

  • Authors: Yong Kim, S. Yeo, H. Rim, Jong-Hyup Lee, Dokyoung Kim et al.
  • Year: 2022
  • Venue: Journal of Clinical Medicine
  • URL: https://www.semanticscholar.org/paper/5c75e1e7aa3ff4e5c3b926a7998ef341b6e0a902
  • DOI: 10.3390/jcm11030888
  • PMID: 35160337
  • PMCID: 8836601
  • Citations: 9
  • Summary: (1) Background: The effectiveness of decompression surgery for Bell’s palsy is controversial. This study investigated the effects of facial nerve decompression in patients with severe Bell’s palsy who were expected to have a poor prognosis. (2) Methods: We retrospectively reviewed 1721 patients with Bell’s palsy who visited the Kyung Hee University Hospital between January 2005 and December 2021. Of these, 45 patients with severe Bell’s palsy were divided into two groups; 30 patients were tre...
  • Evidence snippets:
  • Snippet 1 (score: 0.583) > Bell's palsy is an acute, unilateral, peripheral facial nerve paresis or paralysis of unknown cause. It has an annual incidence of 20-30 per 100,000 population [1,2]. The pathophysiology of Bell's palsy includes edematous swelling of the facial nerve within the Fallopian canal, which causes a conduction block and subsequent dysfunction. However, the exact mechanism of impaired nerve function remains unclear. Although most patients with Bell's palsy have a good prognosis, approximately 10-29% of affected patients develop persistent facial nerve dysfunction [3,4]. Facial nerve lesions determine the shape of the face, which can have a significant impact on an individual's social life. It is important to identify and treat patients at high risk of poor long-term outcomes in order to reduce the risk of persistent facial nerve dysfunction and psychological distress [5]. > There is strong evidence supporting the use of steroids as the initial medical treatment in Bell's palsy to reduce facial nerve inflammation [6,7]. Treatment guidelines for Bell's palsy published by the American Academy of Otolaryngology concluded that treatment with oral steroids within 72 h of symptom onset is highly likely to be effective in new-onset Bell's palsy patients with or without concurrent antiviral therapy [8]. However, some patients do not respond to conservative treatment, and suffer sequelae, including facial asymmetry, contracture, and synkinesis [9]. > Electroneuronography (ENoG) and electromyography (EMG) are objective electrical tests that are used to estimate the degree of paralysis and prognosis in Bell's palsy patients. Patients with Bell's palsy are at a high risk of poor recovery if they demonstrate the following clinical findings: a complete lack of facial movement on clinical examination; ENoG findings of >90% degeneration; and EMG findings of no voluntary motor unit potentials [3,[10][11][12]. > For patients at risk of poor recovery, surgical decompression of the facial nerve has been proposed as an additional treatment option to release nerve entrapment in the facial canal and improve outcomes [13][14][15].

[3] Rehabilitation of a Patient with Bell’s Palsy

  • Authors: Vrushali Athawale, Dushyant Bawiskar, Pratik Phansopkar
  • Year: 2021
  • Venue: Journal of Evolution of Medical and Dental Sciences
  • URL: https://www.semanticscholar.org/paper/590b99acef57798359b4e42aebec24512177ee46
  • DOI: 10.14260/JEMDS/2021/323
  • Citations: 2
  • Summary: This is a diagnosed case of right facial nerve palsy which was treated under physiotherapy department with proper rehabilitation protocol and the aetiology of facial paralysis is not yet thoroughly understood.
  • Evidence snippets:
  • Snippet 1 (score: 0.579) > Facial nerve palsy is the disease of cranial nerve. From the total number of cases, 60 to 75 % of Bell's palsy cases are idiopathic form of facial palsy. Facial nerve palsy results in weakness of facial muscles, atrophy, asymmetry of face and also disturbs the quality of life. Bell’s palsy occurs in every class of population affecting people of all the age groups but the most common age group affected is 15 - 50 years with equal sex prediliction accounting 11 - 40 cases per 100,000. If facial palsy is not treated properly then it may result in variety of complications like motor synkinesis, dysarthria, contractures of facial muscles, and crocodile tear. Currently facial paralysis treatment consists of combination of pharmacological therapy, facial neuromuscular re-entrainment physiotherapy or surgical intervention by static and dynamic facial reanimation techniques. Physiotherapy treatment is effective for treating facial paralysis with minimal complications and can be individualized. Bell's palsy is the idiopathic form of facial nerve palsy which accounts for 60 to 75 % of cases and male to female ratio is 1:3.1 The aetiology of facial paralysis is not yet thoroughly understood. Cases of varicella-zoster, mononucleosis, herpes simplex virus, mumps and measles have demonstrated good serology in several reports for their association but still stands unclear. 2 Peripheral facial nerve palsy may be idiopathic (primary cause) or Bell’s palsy (secondary). Causes of the secondary unilateral facial nerve palsy are diabetes, stroke, Hansen's disease, herpes simplex infection, birth injury, trauma, tumour, Guillain-Barre syndrome, and immune system disorders. Causes of the bilateral facial nerve palsy are leukemia, brainstem encephalitis, leprosy, and meningitis. The most prominent current theories of facial nerve paralysis pathophysiology include the reactivation of herpes simplex virus infection (HSV type 1). Current facial paralysis treatment consists of a combination of pharmacological therapy, facial neuromuscular re-entrainment physiotherapy or surgical intervention by

[4] Emerging Trends in Pathophysiology: Insights from the 9th International Congress of the International Society for Pathophysiology (ISP 2023)

  • Authors: A. Kubyshkin, S. Bolevich, L. Churilov, V. Jakovljevic, E. Kovalenko et al.
  • Year: 2024
  • Venue: Pathophysiology
  • URL: https://www.semanticscholar.org/paper/3ab0c7d37d984c72ca8cba300cb8052c1326e61a
  • DOI: 10.3390/pathophysiology31010011
  • PMID: 38535621
  • PMCID: 10975917
  • Summary: The main trends and the most promising areas of research in current pathophysiology, including investigations of new pathogenic pathways, and the identification of cellular and molecular mechanisms, target molecules, genetic mechanisms, and new therapeutic strategies are described.
  • Evidence snippets:
  • Snippet 1 (score: 0.561) > This article provides a summary of the 9th International Congress of the International Society for Pathophysiology (ISP 2023) which took place in Belgrade, Serbia, from 4 to 6 July 2023. It describes the main trends and the most promising areas of research in current pathophysiology, including investigations of new pathogenic pathways, and the identification of cellular and molecular mechanisms, target molecules, genetic mechanisms, and new therapeutic strategies. The present article also highlights the research conducted by leading scientific teams and national pathophysiological societies from various countries that adds to our understanding of the pathogenesis of diseases and pathological processes.

[5] New onset of Bell’s palsy in a patient with West Nile Encephalitis

  • Authors: Tetyana Vaysman, A. Melkonyan, Antonio Liu
  • Year: 2020
  • Venue: Clinical Case Reports
  • URL: https://www.semanticscholar.org/paper/7f39c432dfee57947bfa6da4682be36e7a2d5966
  • DOI: 10.1002/ccr3.3009
  • PMID: 33088514
  • PMCID: 7562893
  • Citations: 2
  • Summary: A patient who was diagnosed with West Nile virus encephalitis and developed new onset of Bell's palsy within 8 days of diagnosis and it would be beneficial to evaluate WNV‐infected patients for peripheral neuropathy.
  • Evidence snippets:
  • Snippet 1 (score: 0.555) > ess than 1% of affected people develop neuroinvasive disease and mortality rate accounts for <0.1% of all WNVinfected patients. 8 ell's palsy is an idiopathic facial nerve paralysis which often presents with unilateral facial weakness commonly characterized by an inability to close the eye, disappearance of the nasolabial fold, and eyebrow drooping at the affected corner of the mouth. There may also be decreased tearing, hyperacusis, and/or loss of taste sensation on the anterior two thirds of the tongue. 10 The nerve paralysis was named after Scottish physician, surgeon, and neurologist Charles Bell (1774-1842) who first described the lesions of facial nerve (CN VII) and its clinical presentations. 11 It has been widely accepted that herpes simplex virus and herpes zoster virus are the most common etiology of Bell's palsy. Other viral infectious agents such as Epstein-Barr Virus, cytomegalovirus, rubella, mumps virus, adenovirus, influenza B virus, and coxsackievirus have been reported. 12 However, there are no known reports of development of Bell's palsy with WNV encephalitis. The annual incidence of Bell's palsy is 40 000 new cases each year with 8% to 12% recurrence rate. 13 Up to 70% of patients will have complete resolution without treatment. 14 ven though the underlying pathophysiology remains elusive, Bell's palsy is thought to result due to virus-mediated inflammation resulting in swelling of the CN VII and its compression at the geniculate ganglion. 12

[6] Action Plan for Stroke in Europe 2018–2030

  • Authors: B. Norrving, J. Barrick, A. Dávalos, M. Dichgans, C. Cordonnier et al.
  • Year: 2018
  • Venue: European Stroke Journal
  • URL: https://www.semanticscholar.org/paper/0f21747f78323fb499a020962145d0be1cb425a9
  • DOI: 10.1177/2396987318808719
  • PMID: 31236480
  • PMCID: 6571507
  • Citations: 468
  • Influential citations: 28
  • Summary: The ESAP provides a basic road map and sets targets for the implementation of evidence-based preventive actions and stroke services to 2030 and overall, 30 targets and 72 research priorities were identified for the seven domains.
  • Evidence snippets:
  • Snippet 1 (score: 0.552) > c strokes, and a major cause of intracerebral haemorrhage, vascular cognitive impairment or dementia. Incomplete understanding of SVD pathogenesis and a lack of appropriate animal models are obstacles to progress. Large-scale studies of systems biology can provide insights into the underlying mechanisms of complex diseases and responses to treatment. 109 Key priorities in this area include: better understanding of the pathogenic contribution of endothelial dysfunction or BBB disruption, inflammation and hemodynamic factors; understanding the role of proteins and pathways involved in monogenic forms of SVD and (multifactorial) sporadic SVD; 110 understanding the mechanisms leading to cognitive impairment and deciphering the intricate relationship with Alzheimer's disease; designing protective approaches to reduce progression of white matter damage; expanding the identification of genetic and other molecular biomarkers and translating the new putative targets discovered through genetic, molecular and cellular biology data into diseasemodifying therapies. > Functional recovery and rehabilitation. A key objective is to expand our knowledge on functional recovery mechanisms and potential therapeutic targets to enhance the effects of physical rehabilitation in the chronic phase after stroke. Research is needed on neuronal plasticity and network recovery, and their interaction with delayed pathophysiological mechanisms such as neuroinflammation, apoptosis, neurogenesis and angiogenesis. This will require the adoption of methodology from stem cell research, gene therapy, optogenetics, non-invasive brain stimulation and other fields. The methodology for evaluating functional recovery in experimental stroke models should be improved.

[7] Psychosocial functioning in patients with altered facial expression: a scoping review in five neurological diseases

  • Authors: N. Rasing, W. van de Geest-Buit, On Ying A Chan, K. Mul, A. Lanser et al.
  • Year: 2023
  • Venue: Disability and Rehabilitation
  • URL: https://www.semanticscholar.org/paper/df39d3d69ccc1115843457a6070c199396eca110
  • DOI: 10.1080/09638288.2023.2259310
  • PMID: 37752723
  • Citations: 10
  • Summary: Patients with altered facial expression in four of five included neurological diseases had reduced psychosocial functioning, and learning of compensatory strategies could be a beneficial therapy for patients with psychosocial distress.
  • Evidence snippets:
  • Snippet 1 (score: 0.551) > A systematic review on psychosocial distress in facial palsy patients has recently been performed, but other neurological diseases were not included [12]. Our review has a different starting point by including five neurological disorders (i.e., neuromuscular and movement disorders) and also including smaller studies (case reports) to maximize existing knowledge to give insight on the common themes of having an altered facial expression on psychosocial functioning. > We included five neurological diseases: Bell's palsy, FSHD, Moebius syndrome, myotonic dystrophy type 1, and Parkinson's disease. These diseases have a very different pathophysiology, but can all cause an altered facial expression. This selection of diseases was chosen carefully to ensure a diverse overview of possible causes of altered facial expression: acute versus gradual onset, congenital versus acquired disease, and different aetiologies. Figure 2 highlights the similarities and differences between the diseases. The psychosocial study outcomes in these diseases are expected to create an understanding of the possible psychosocial impairments of having an altered facial expression and to help identify future research directions for improving verbal and non-verbal communication, and thus psychosocial functioning.

[8] Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases

  • Authors: N. Rasing, W. van de Geest-Buit, On Ying A Chan, K. Mul, A. Lanser et al.
  • Year: 2024
  • Venue: Journal of Neuromuscular Diseases
  • URL: https://www.semanticscholar.org/paper/8a055850bd49d4c16be74241b5086c5e4a2a7406
  • DOI: 10.3233/JND-230213
  • PMID: 38517799
  • PMCID: 11091602
  • Citations: 3
  • Summary: A systematic search for symptomatic treatment approaches that target facial muscle function and psychosocial interventions in various neurological diseases with altered facial expression in order to discuss the applicability to FSHD found forty studies met the inclusion criteria.
  • Evidence snippets:
  • Snippet 1 (score: 0.542) > Multiple neurological diseases were included, because of the expected scarcity of literature about treatment options for improving facial weakness in FSHD patients and of the expected wide applicability of certain symptomatic treatments.However, the anatomical location of the defect and the pathophysiology is different in these diseases (Fig. 2), therefore some recommended treatments are not applicable to FSHD. > When comparing the included diseases on altered facial expression, especially Parkinson's disease has a different underlying mechanism.As bradykinesia causes the altered facial expression, whereas in the other included disease this is caused by facial weakness or facial paresis.Additionally, medication and associated on-off phenomenon can effect the degree of bradykinesia, potentially affecting the outcomes of symptomatic treatments.However, the included studies did provide valuable insights into current symptomatic therapies, which could be discussed for their potential applicability in FSHD. > Bell's palsy patients have a high spontaneous recovery rate, as about seventy percent has a spontaneous recovery within three to six months [93].Therefore, in studies with Bell's palsy patients a high number of patients recovering after treatment, would also recover without treatment.Treatment effectivity could therefore be overestimated in this disease, this applies especially for studies performed in the acute phase of Bell's palsy. > Of the included studies, 12 consisted of case reports.Level of evidence is low, and conclusions must be taken with caution.Nevertheless, these studies were included because they could point out treatment options that would otherwise not be identified and might be interesting for future research. > Studies performed before 1990 were excluded, because of the expected outdated treatment usage before 1990, especially for surgery techniques.Despite we could have missed important references.

[9] Lower motor neuron facial palsy in a postnatal mother with COVID-19

  • Authors: Vignesh Kumar, P. Narayanan, Seema Shetty, Afsal P Mohammed
  • Year: 2021
  • Venue: BMJ Case Reports
  • URL: https://www.semanticscholar.org/paper/b69d9ac169040035e4f502469c82c94be2374938
  • DOI: 10.1136/bcr-2020-240267
  • PMID: 33649026
  • PMCID: 7929834
  • Citations: 17
  • Influential citations: 2
  • Summary: The authors present a case of Bell’s palsy associated with COVID-19 in a term primigravida.
  • Evidence snippets:
  • Snippet 1 (score: 0.538) > Bell's palsy is the most common cause of acute unilateral lower motor neuron facial nerve palsy. The worldwide incidence of Bell's palsy varies between 11.5 and 40.2 cases per 100 000 population. 9 Bell's palsy has been associated with viral infections like Epstein-Barr virus, mumps, rubella, and most commonly, HSV. A cell-mediated autoimmune response against myelin basic protein has been linked with Bell's palsy. 10 Risk factors for Bell's palsy include pregnancy, severe preeclampsia, obesity, upper respiratory diseases, hypertension and diabetes. The pathophysiology of Bell's palsy has been a topic of intense debate. Some authors describe it as an acute demyelinating disease similar to Guillain-Barré disease. 11 Murakami et al successfully isolated Herpes simplex-1 DNA from the endoneurial fluid of the facial nerve by PCR during the acute phase of Bell's palsy. 12 Autoimmune or virus-mediated damage to facial nerve leads to oedema of the nerve and causes lower motor neuron palsy. > COVID-19 has a deleterious effect on the nervous system ranging from anosmia, dysgeusia to acute stroke. Autopsy reports in patient's with COVID-19 has shown brain tissue oedema and partial neuronal degeneration in deceased patients. 13 Moriguchi et al reported a case of COVID-19 where the patient had a loss of consciousness, seizures, neck stiffness. SARS-CoV-2 RNA was isolated from the cerebrospinal fluid (CSF) though it was absent in the nasopharyngeal swab, providing further evidence that SARS-CoV-2 is a neurotropic virus. 14 Viral encephalitis, meningitis, encephalopathy, demyelination and acute cerebrovascular accidents have been reported in COVID-19 patients. 15 The mechanism of neuroinvasion by SARS-CoV-2 could be a direct invasion of the nervous system or entry through the blood circulation. Coronaviruses have been known to infect sensory or motor nerve endings achieving anterograde

[10] Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis

  • Authors: Minhao Qiu, Xiaoying Zhou, M. Zippi, Hemant Goyal, Zarrin Basharat et al.
  • Year: 2023
  • Venue: Annals of Medicine
  • URL: https://www.semanticscholar.org/paper/45eb6adcd7600f6a642f6adcf51182e2de45ba30
  • DOI: 10.1080/07853890.2023.2265939
  • PMID: 37813108
  • PMCID: 10563627
  • Citations: 44
  • Influential citations: 1
  • Summary: An overview of triglyceride metabolism and the potential mechanisms that may contribute to developing or exacerbating hypertriglyceridaemia appears promising, with ongoing research focused on developing more specific and effective treatment strategies.
  • Evidence snippets:
  • Snippet 1 (score: 0.537) > HTAP is a complex disease with a multifactorial aetiology, and not fully understood pathophysiology.As our knowledge regarding the disease evolves, we are likely to develop more effective and targeted treatments, which can reduce the occurrence of more severe disease outcomes or prevent the disease altogether.Future research will need to focus on elucidating the underlying genetic and molecular mechanisms of the disease, as well as identifying specific pathways and targets that can be used to develop more effective treatments.This will require a multidisciplinary approach that combines genetics, molecular biology, and clinical research and will likely involve collaborations between basic and clinical scientists across multiple disciplines.Ultimately, developing more effective treatments for HTAP will require a deep understanding of the underlying pathophysiology of the disease, as well as the development of more targeted and personalized approaches to diagnosis and treatment.

[11] Increased risk of Bell palsy in patient with migraine

  • Authors: So Young Kim, C. Lee, Jae-Sung Lim, I. Kong, Songyong Sim et al.
  • Year: 2019
  • Venue: Medicine
  • URL: https://www.semanticscholar.org/paper/63ff6044765415b3c757a54ffc245b1d3ce880b3
  • DOI: 10.1097/MD.0000000000015764
  • PMID: 31124964
  • PMCID: 6571209
  • Citations: 10
  • Influential citations: 2
  • Summary: Migraine increased the risk of Bell palsy in the total population and among age subgroups, migraine patients ≥30 and <60 years old had an increased risk ofBell palsy.
  • Evidence snippets:
  • Snippet 1 (score: 0.536) > In the present study, migraine was found to increase the risk of Bell palsy. This increased risk in migraine patients was evident in the ≥30 and <60-year-old population. Few previous studies have reported a relationship between migraine headaches and Bell palsy. The details of the pathophysiology of Bell palsy have not been completely unraveled. Vascular ischemia, immunologic disorders, infectious diseases, and psychological disorders have all been suggested to be associated with Bell palsy. [1] Thus, migraine headaches could also contribute to various aspects of the pathophysiologic mechanism(s) leading to Bell palsy. > The direct neural effects from the trigeminal nerve to the facial nerve could contribute to the risk of facial palsy in migraine patients. A case was reported of a 32-year-old woman with migraine who suffered from recurrent facial paralysis. [11] That study proposed that a reciprocal connection between the trigeminal nerve and the facial nerve could explain the concurrent trigeminal neuralgia and facial palsy. Specifically, the sensory pain afferents of the nervus intermedius, which branches from the maxillary nerve, innervate the facial nerve. [12] However, the concurrent peripheral neural dysfunction of both the trigeminal and facial nerves is rare. In addition to concurrent trigeminal and facial nerve dysfunction, the facial nerve could be gradually weakened leading to paralysis in migraine patients. Repetitive nociceptive neural stimuli in these patients may increase the susceptibility of the facial nerve to injury. > Common pathophysiologic mechanisms exist that could underlie both migraine and Bell palsy. For instance, cardiovascular ischemia is a risk factor for both conditions. [13] lthough the pathophysiologic mechanism of migraines is not completely understood, alteration of the trigeminovascular function has been suggested to trigger migraines. [14,15] Aura migraines are thought to result from a cortical spreading depression induced by cerebral ischemia and inhibition of neural activity. [15,16] Prior studies have demonstrated a 2-fold increase in the risk of stroke and cardiovascular diseases in migraine patients. [17]

[12] Unilateral Facial Paralysis in an Infant Post-vaccination: Insights Into Bell’s Palsy

  • Authors: Sonal Kumar, Adnan A Islam, Patricia Ward, Taylor E Collignon, A. Castro
  • Year: 2025
  • Venue: Cureus
  • URL: https://www.semanticscholar.org/paper/c15f53d1f9da48f89eccd7c914ddefb4de595984
  • DOI: 10.7759/cureus.79971
  • PMID: 40182388
  • PMCID: 11966339
  • Summary: The story of a unique instance of Bell’s palsy in a two-month-old infant with unilateral facial paralysis one day following standard immunizations is shared, highlighting the need for further investigation into the risk of post-vaccination neurological complications, particularly in the pediatric population.
  • Evidence snippets:
  • Snippet 1 (score: 0.525) > Bell's palsy is an acute FNP associated mostly with viral infections, autoimmune conditions, and inflammatory processes. It commonly presents in adults. Pediatric presentations are, therefore, uncommon. While the pathophysiology of Bell's palsy is unclear, reactivation of HSV in the geniculate ganglion is a leading hypothesis [5]. Triggers such as EBV, VZV, and immune-mediated mechanisms may also contribute [6]. > Our case presentation is an important addition to the literature because we discuss the temporal relationship between the onset of Bell's palsy and the administration of the infant's routine two-month vaccinations. Bell's palsy occurring following vaccination is reported in the literature, though it remains an uncommon event [7]. Literature has described cases of FNP following the administration of vaccines such as the COVID-19 vaccination [8], hepatitis B vaccine [9], and HPV vaccine [10]. These associations may suggest that an immune-mediated response is responsible. Still, however, more epidemiological studies are warranted as a causal link between vaccination and Bell's palsy has not been established [11]. > One proposed mechanism for post-vaccination Bell's palsy includes an immune-mediated inflammatory reaction leading to facial nerve edema and compression in the facial canal [12]. Molecular mimicry where vaccine antigens trigger an immune response that cross-reacts with host neural tissues has also been proposed as another mechanism [12]. However, given the overall rarity of Bell's palsy following immunization, the risk remains low compared to the benefits of vaccination in preventing serious infectious diseases. > Future studies such as large-scale surveillance data and population-based cohort studies are necessary to clarify such proposed associations. Clinicians must remain vigilant for post-vaccination neurological events yet still advocate for routine immunization given the overall public health benefits.

[13] A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data

  • Authors: Yuchao Liu, Chunli Li, Linli Yao, Miao Tian, Yuan Tan et al.
  • Year: 2025
  • Venue: Cellular and Molecular Neurobiology
  • URL: https://www.semanticscholar.org/paper/a2ebd0eb0eb2a2b91933d7493d52a120cc1e03df
  • DOI: 10.1007/s10571-025-01607-4
  • PMID: 41099890
  • PMCID: 12532790
  • Citations: 1
  • Summary: This study successfully identified SLIT2 as potential therapeutic targets for PFP and detected SLIT2 alteration after facial-nerve injury, a role that has been previously well-documented in many central nervous system diseases.
  • Evidence snippets:
  • Snippet 1 (score: 0.518) > Peripheral facial paralysis (PFP) is a common neurological disorder characterized by facial-nerve dysfunction. Identifying therapeutic targets and understanding the molecular and cellular mechanisms underlying PFP are crucial for developing effective treatment strategies. This study combined Mendelian randomization (MR) analysis and single-cell RNA sequencing (scRNA-seq) to explore potential therapeutic candidates and their roles in PFP pathophysiology. The MR analysis included 1925 publicly available plasma protein cis-heritability instruments. Instrumental variables were selected for MR analysis to identify plasma proteins associated with PFP, followed by colocalization analysis to evaluate shared genetic variants between the identified proteins and PFP. After the initial identification of plasma proteins associated with Bell’s palsy using MR analysis, a rat model of facial-nerve injury was established to further dissect underlying mechanisms at cellular and molecular levels. Using scRNA-seq technology, we delved deeply into cellular Heterogeneity and dynamic changes in gene expression in the facial-nerve nucleus tissues under both injured and control conditions, thereby achieving a systematic study ranging from macroscopic genetic associations to microscopic cellular functions. Finally, expression patterns were preliminarily validated by performing in vitro immunofluorescence analysis on the facial-nerve nucleus samples of SD rats. The MR analysis results identified 30 plasma proteins significantly associated with PFP, with nine target genes showing differential expression in the scRNA-seq data. Colocalization analysis demonstrated that slit guidance Ligand 2 (SLIT2), semaphorin 4D (SEMA4D), EGF containing fibulin extracellular matrix protein 1 (EFEMP1), and sprouty related EVH1 domain containing 2 (SPRED2) shared causal variants with PFP. SLIT2 was highly expressed in the microglia and inhibitory neurons in the experimental group, whereas SEMA4D showed elevated expression across multiple glial cell types in the same group. In contrast, EFEMP1 and SPRED2 showed distinct expression patterns in fibroblasts and oligodendrocytes. The role of SLIT2 has been previously well-documented in many central nervous system diseases. However, for the first time, this study detected SLIT2 alteration after facial-nerve injury. Altered intercellular signaling, particularly enhanced SLIT2-ROBO signaling between neurons and

[14] Of Mice and Men: Comparative Analysis of Neuro-Inflammatory Mechanisms in Human and Mouse Using Cause-and-Effect Models

  • Authors: A. Kodamullil, Anandhi Iyappan, Reagon Karki, S. Madan, E. Younesi et al.
  • Year: 2017
  • Venue: Journal of Alzheimer's Disease
  • URL: https://www.semanticscholar.org/paper/55820fd5fc6231bc4bf3c0330cb6cbfea9a4827c
  • DOI: 10.3233/JAD-170255
  • PMID: 28731442
  • PMCID: 5545904
  • Citations: 27
  • Summary: This paper investigates the failure of a neuroinflammation targeted drug in the late phases of clinical trials based on the comparative analyses between the two species and assesses to what extend a mouse can mimic the cellular and molecular interactions in humans at a mechanism level.
  • Evidence snippets:
  • Snippet 1 (score: 0.518) > Mouse models are extensively used in biomedical research mainly to understand the etiology of the disease. Complex diseases like AD may involve several simultaneous alterations in molecular and processual activities, including neuroinflammation, aggregation of A␤ peptides, or tau phosphorylation, which are likely to contribute to pathophysiology. In this paper, we have compared the mouse and human at molecular, cellular, and pathway levels to shed light on mechanistic differences with important implications for translation outcomes. Mechanistic modelling specific to species allows us to "embed" and "represent" similarities and differences in innate immunity which can lead to the development of "conflictious information detection engine". It is important to note that our analysis is purely based on the research and publication bias in mouse and human experiments as many mouse experiments are mainly focused on particular explorative areas, and experiments with human tissues are also concentrated on limited areas of disease mechanism. We found that mouse experiments often reveal new molecular interactions between different entities that are not observed or reported in human experiments. Differential analysis of mouse and human model for neuroinflammation shows that mouse and human differ at the molecular and cellular levels, but have more similarities at the pathway levels as numbers indicate. More explicitly, the underlying molecular patterns which lead to a particular bioprocess differ between the two species. This finding implies that although the two species share some similarities at the cellular or pathway level, the pattern of molecular interactions that form, govern, and regulate those pathways is substantially different between mouse and human. > It is notable that mouse models have provided significant insights into many disease areas like cancer; acute promyelocytic leukemia. However, recent drug failures in the area of neurodegeneration have put a question mark behind the extent to which mouse models have been used in preclinical drug discovery and to what extent transgenic mice mimic human brain pathophysiology mechanisms. Pathophysiology mechanisms are likely to act together and they seem to be organized in a temporal cascade of events that ultimately result in a severe disease phenotype. Experiments with single gene knock-out in mice can reveal only minor aspects of the disease perturbations and do not usually allow us to decipher the full complexity of the mechanisms underlying the disease.

[15] Exploring the Role of Inflammation and Metabolites in Bell’s Palsy and Potential Treatment Strategies

  • Authors: Jiaye Lu, Ziqian Yin, Youjia Qiu, Yayi Yang, Zhouqing Chen et al.
  • Year: 2025
  • Venue: Biomedicines
  • URL: https://www.semanticscholar.org/paper/4ce13514569cb37f6aab52f4f13df3e4578cae50
  • DOI: 10.3390/biomedicines13040957
  • PMID: 40299566
  • PMCID: 12024589
  • Citations: 2
  • Summary: This study identifies causal relationships between inflammatory proteins, metabolites, immune cells, and Bell’s palsy, highlighting that the JAK/STAT signaling pathway may be a potentially critical target for intervention in Bell’s palsy and that its modulation may provide new directions and opportunities for therapeutic strategies and drug discovery for the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.514) > Further KEGG pathway analyses highlighted the potential role of cytokine-cytokine receptor interactions and rheumatoid arthritis pathways in the pathogenesis of Bell's palsy, further supporting the association of the disease with neuroinflammation, immune imbalance and infection. > To further elucidate the potential role of inflammatory immune-related proteins in Bell palsy, we constructed a PPI network and screened 31 high-confidence interacting proteins, among which IL-6 showed a high degree of connectivity. Further analysis showed that VCAM-1, CCL19, IL27RA and IL-6 play important roles in immunomodulation, cell adhesion, inflammatory response and immune cell migration. In addition, based on the MCODE plugin, we identified six core proteins, including VCAM-1, CCL19, IL27RA, OSM, SELL and JAK2, of which VCAM-1, CCL19, OSM and IL27RA passed co-localization analysis. > Our research suggests that CCL19, SELL and VCAM-1 may promote inflammatory cell infiltration and nerve injury through synergistic effects in the pathology of Bell's palsy, and although there is no clear signaling axis linking the three indirect crosstalk, their joint role in immune cell recruitment and vascular endothelial activation may be key to the onset and progression of the disease [25][26][27]. CCL19 acts as a chemokine that attracts T cells and dendritic cells to migrate toward inflammatory sites, whereas SELL, as an adhesion molecule, plays an important role in leukocyte rolling and adhesion, facilitating the penetration of immune cells through the vascular wall and into diseased tissues, which synergistically enhances local inflammatory responses with CCL19 [25,28]. In addition, this process may be further amplified by the up-regulation of VCAM-1 expression, which promotes strong binding of immune cells to endothelial cells by binding to VLA-4 and increases the permeability of the blood-nerve barrier, allowing more immune cells to penetrate into peripheral tissues of the facial nerve, thereby exacerbating local inflammation and nerve injury [26,29].

[16] The use of intra-cellular signaling pathways in anesthesiology and pain medicine field.

  • Authors: J. Joo
  • Year: 2009
  • Venue: Korean journal of anesthesiology
  • URL: https://www.semanticscholar.org/paper/d20f7ea110adebeb95be021611d90522a87a42c1
  • DOI: 10.4097/kjae.2009.57.3.277
  • PMID: 30625873
  • Citations: 1
  • Summary: If efforts are focused on applying the new cellular and molecular biologic research, these efforts could identify the mechanism of diseases and help develop new drugs in the field of anesthesiology and pain medicine.
  • Evidence snippets:
  • Snippet 1 (score: 0.503) > At the level of individual cells, signaling is crucial in cell division, differentiation, metabolic control and death. Reception of the signals depends on receptor proteins that are usually at the cell surface, and these receptor proteins bind the signal molecule. The binding activates the receptor, which in turn activates one or more of the intra-cellular signaling pathways. These relay chains of molecules, mainly intra-cellular signaling proteins, process the signal inside the receiving cell and distribute it to the appropriate intra-cellular targets. Cell signaling pathways are involved in the pathophysiology of many diseases and also in the mechanisms of action of many drugs, including local and general anesthetics. Knowledge of the basic cell signaling mechanisms is essential for understanding many of the pathophysiologic and pharmacologic mechanisms. Therefore, if we focus on applying the new cellular and molecular biologic research, these efforts could identify the mechanism of diseases and help develop new drugs in the field of anesthesiology and pain medicine.

[17] Clinical Prognostic Factors Associated with Good Outcomes in Pediatric Bell’s Palsy

  • Authors: M. Yoo, D. Park, J. Byun, S. Yeo
  • Year: 2021
  • Venue: Journal of Clinical Medicine
  • URL: https://www.semanticscholar.org/paper/2c0e8d61a7ba5cc7f717091b0dde0ecd37b8d825
  • DOI: 10.3390/jcm10194368
  • PMID: 34640384
  • PMCID: 8509832
  • Citations: 13
  • Summary: The results showed that the most important factor influencing the complete recovery of Bell’s palsy in children was the lower initial H–B grade at initial presentation.
  • Evidence snippets:
  • Snippet 1 (score: 0.500) > Acute peripheral facial palsy is uncommon in children, with an annual incidence ranging from 5 to 21 per 100,000 children [1,2]. Idiopathic facial paralysis, known as Bell's palsy, is a disease characterized by acute, unilateral, idiopathic peripheral facial palsy [3]. Unilateral facial weakness of unknown cause develops rapidly, with Bell's palsy considered the most common cause of facial paralysis in children compared with other etiologies, including traumatic, congenital, infectious and neoplastic causes [4][5][6]. The etiology and pathophysiology of Bell's palsy in children are not completely understood. It can be caused by inflammation and edema of the facial nerve fibers, with infiltration of lymphocytes and associated demyelination or axonal degeneration [7,8]. Moreover, infections with many viruses have been reported to cause acute peripheral facial paralysis in children. These findings have suggested that treatment with corticosteroids and/or antiviral agents may be effective in patients with Bell's palsy. Corticosteroid treatment of adults was shown to improve their chances of recovery, especially if treatment is started within 72 h of symptom onset [9]. In contrast to adults, the clinical prognosis of Bell's palsy in children is not well documented. To date, there has been a relative lack of research on the prevalence, treatment, and outcomes of Bell's palsy in children and no standardized treatment guidelines have yet been developed. Therefore, the treatment of children, including the types and dosages of corticosteroids and antiviral agents, is empirical, based on each physician's experience. > The natural progression of Bell's palsy in children is thought to be good, with many children tending to show favorable recovery within two months and most by six months, with spontaneous recovery occurring in up to 90% of children under the age of 14 years [10,11]. > However, the degree of paralysis at onset can affect the degree of recovery and, in the case of severe paralysis, patients are rarely known to achieve a complete recovery of the nerve function [12,13].

[18] Construction of neural system disease models from the perspective of cellular biomechanics and their application in teaching practice

  • Authors: Hong Xue, Qiong Zhao, Zhilan Zhao, Ruozhao Li, Guangyu Li
  • Year: 2025
  • Venue: Frontiers in Bioengineering and Biotechnology
  • URL: https://www.semanticscholar.org/paper/d9021c44bd3dca261a0cc5378c6fdd99e89d7127
  • DOI: 10.3389/fbioe.2025.1715222
  • PMID: 41480584
  • PMCID: 12754723
  • Summary: This approach prepares future healthcare professionals to address complex neurological disorders more effectively by bridging biomechanical insights with clinical and teaching applications, and enriches both research and educational practices.
  • Evidence snippets:
  • Snippet 1 (score: 0.500) > Neurological diseases, including Parkinson's disease, Alzheimer's disease, and stroke, pose a substantial global health burden, impacting millions of individuals and their families worldwide. The World Health Organization has recognized these conditions as critical public health challenges, necessitating urgent attention and innovative approaches to treatment and education. In this context, Maryam (2023) provides a comprehensive overview of the molecular genetic perspective on neurological diseases, emphasizing the complex interplay between genetic predispositions and environmental influences that contribute to the pathogenesis of these disorders. This multifaceted understanding is crucial for developing targeted therapeutic strategies that address the underlying mechanisms of disease progression (Maryam, 2023). > Moreover, Sharma (2022) highlights the emerging interrelationship between the gut microbiome and cellular senescence, suggesting that these factors may significantly influence the onset and progression of neurological diseases. This perspective underscores the importance of considering not only the central nervous system but also peripheral factors that may impact neurological health. The intricate connections between cellular mechanisms and biomechanical processes are vital for elucidating the pathophysiology of neurodegenerative conditions and motor dysfunctions, which often manifest as debilitating symptoms in affected individuals (Sharm, 2022). > The construction of accurate and representative disease models is essential for advancing our understanding of these complex disorders. Such models facilitate the analysis of pathological mechanisms, allowing researchers to investigate the effects of various interventions and treatments. Furthermore, the implications of these models extend beyond research; they hold significant value for educational practices. By integrating cellular biomechanics and disease modeling into the curriculum, educators can provide students with a more comprehensive understanding of neurological diseases, fostering critical thinking and problemsolving skills. This dual significance of model construction-both for elucidating pathological mechanisms and enhancing educational practices-highlights the necessity of incorporating biomechanical perspectives into the study of neurological disorders (Jnana Therapeutics, 2020).

[19] Understanding the Pathophysiology of Atopic Dermatitis – insights into Immune Dysregulation and Skin Barrier Dysfunction

  • Authors: Maja Kucharska, Kacper Kwiliński, Barbara Wawrzyńska, Marlena Cąkała, Adrian Kruszewski et al.
  • Year: 2024
  • Venue: Quality in Sport
  • URL: https://www.semanticscholar.org/paper/9ba8ec050f511e04ecb6b80a72906f5c9323e629
  • DOI: 10.12775/qs.2024.19.54073
  • Summary: Atopic dermatitis is a complex, chronic inflammatory skin disease with a multifaceted pathophysiology involving genetic, immunological, and environmental factors including filaggrin mutations, Th2 cytokine-mediated inflammation, and the skin microbiome.
  • Evidence snippets:
  • Snippet 1 (score: 0.498) > Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disrupted skin barrier and immune dysregulation. The exact pathophysiology of atopic dermatitis despite extensive research remains complex. It includes genetic disorders, a defect in the epidermal barrier, an altered immune response, and disruption of the skin’s microbial balance. Recent advances in research have provided deeper insights into the molecular mechanisms including the role of filaggrin mutations, Th2 cytokine-mediated inflammation, and the skin microbiome. Understanding the intricate interplay between these components is crucial for developing targeted therapeutic strategies. > Aim of the study: This review provides a comprehensive overview of the current knowledge on the pathophysiological mechanisms underlying AD, highlighting recent advances and areas for future research. > Material and methods: Comprehensive literature searches were performed across the main electronic databases of PubMed and GoogleScholar using the keywords: “atopic dermatitis”, “eczema pathophysiology”, “skin barrier”. > Conclusions: Atopic dermatitis (AD) is a complex, chronic inflammatory skin disease with a multifaceted pathophysiology involving genetic, immunological, and environmental factors. Recent advances in understanding the molecular mechanisms underlying AD have highlighted the importance of skin barrier dysfunction, immune system dysregulation, and microbial interactions in the disease's progression.

[20] Skin Development and Disease: A Molecular Perspective

  • Authors: Iasonas Dermitzakis, Despoina Chatzi, Stella Aikaterini Kyriakoudi, Nikolaos Evangelidis, E. Vakirlis et al.
  • Year: 2024
  • Venue: Current Issues in Molecular Biology
  • URL: https://www.semanticscholar.org/paper/3b0d602b335c265102e2a9f169bab20f51343212
  • DOI: 10.3390/cimb46080487
  • PMID: 39194704
  • PMCID: 11353016
  • Citations: 15
  • Influential citations: 1
  • Summary: By delving into the molecular mechanisms implicated in developmental processes, as well as in the pathogenesis of diseases, a comprehensive understanding of these aspects paves the way for developing innovative targeted therapies and personalised treatment approaches for various skin conditions.
  • Evidence snippets:
  • Snippet 1 (score: 0.497) > Understanding the molecular mechanisms underlying congenital skin diseases and cancer has significantly advanced in recent years, providing crucial insights into the pathogenesis of these conditions. Researchers have uncovered key genetic mutations, signalling cascades, and cellular interactions that drive the development and progression of these disorders by unravelling the intricate molecular pathways affected. This section emphasises that the various molecular signals involved in embryonic development are also implicated in the pathophysiology of certain congenital skin diseases and types of cancer. Analysing these connections provides valuable insights into the molecular mechanisms underlying both skin development and the pathogenesis of skin cancers, such as basal cell and squamous cell carcinoma. Skin cancers often stem from disruptions in essential biological pathways that are also involved in normal skin development. Therefore, identifying these specific molecules can pave the way for developing new targeted therapies through laboratory-based interventions.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.